High-throughput methods for preparing lipid nanoparticles and uses thereof
Patent Information
- Application Number
- JP2023534898
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2020-12-09
- Filing Date
- 2021-12-08
- Publication Date
- 2024-11-21
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Existing lipid nanoparticle (LNP) formulations face challenges in quality control due to complex physicochemical properties, requiring high-throughput screening methods for optimizing lipid composition and payload encapsulation efficiency.
A high-throughput screening method using a robotic liquid handler for solvent injection and mixing of aqueous and organic phases to form lipid nanoparticles, allowing for rapid optimization of lipid composition, payload loading, and formulation parameters.
This method enables efficient production of lipid nanoparticles with high encapsulation efficiency and consistent size distribution, reducing material consumption and processing time while maintaining stability over time.
Smart Images

Figure 00000059_0000 
Figure 00000059_0001 
Figure 00000059_0002
Abstract
Description
[Technical Field]
[0001] Related applications This application claims priority and interest in U.S. Provisional Patent Application No. 63 / 123,343, filed on 9 December 2020, the entire contents of which are incorporated herein by reference for any purpose. [Background technology]
[0002] background Lipid nanoparticles (LNPs) have been widely developed as a biocompatible and stable drug delivery platform. The lipids used to prepare lipid nanoparticles are typically low-toxicity physiological lipids (biocompatible and biodegradable). The physicochemical diversity and biocompatibility of lipids, as well as their ability to enhance the oral bioavailability of drugs, make lipid nanoparticles highly attractive carriers for drug delivery. Furthermore, lipid-based formulations can positively impact drug absorption in several ways, including increased solubilization capacity, prevention of drug precipitation against enteric dilution, enhanced membrane permeability, inhibition of efflux transporters, reduction of CYP enzymes, and enhancement of chylomicron production and lymphatic transport. LNPs are the primary non-viral carrier for siRNA delivery and were used in 70% of nanopharmaceutical clinical trials as of 2019. (Anselmo S et al., 2019, Bioeng.Transl.Med.4(3):e10143.)
[0003] Lipid-based nanocarriers present further challenges in quality control of drug products, partly due to their complex physicochemical properties. According to guidance on liposomal drug products recently published by the U.S. FDA, these formulations should be specified for quality attributes including particle structure and size distribution, physicochemical properties of the particle surface, lipid content, amount and encapsulation efficiency of free APIs, and physical and chemical stability. Different preparation conditions and parameters can affect the quality attributes of LNP formulations. For example, lipid composition, particularly the incorporation of PEGylated lipids in different amounts and / or molecular weights, significantly affected the colloidal stability, cellular uptake, and pharmacokinetics of liposomes (see, e.g., Allen et al., 1991, Biochem Biophys Acta, 1066(1):29-36; Garbuzenko et al., 2005, Chem Phys Lipids, 135(2):117-29; Immordino et al., Int J Nanomedicine 1(3)(2006)297-315), while siRNA or ASO loading can be regulated by charge-mediated interactions with cationic lipids (Schroeder et al., 2010, J Intern Med 267(1):9-21; Cullis et al., 2017, Mol Ther 25(7):1467-1475). The downstream performance of LNPs is also highly dependent on their quality attributes. Therefore, screening these parameters at various levels greatly necessitates a high-throughput approach with simple procedures and multiple analytical outputs. [Overview of the project]
[0004] Summary of the Invention To address the need for screening and optimization of lipid-based nanopharmaceuticals, this disclosure provides a high-throughput screening (HTS) workflow for preparing such lipid-based nanoparticles to encapsulate various therapeutic payloads. In various embodiments, the present invention provides an optimized solvent injection method for the easy self-assembly of LNPs using a robotic liquid handler. In various embodiments, optimal lipid composition, total lipid concentration, and payload loading are described.
[0005] In various embodiments, the disclosure relates to an optimized high-throughput screening method for producing lipid nanoparticle (LNP) preparations, the method comprising: a) obtaining a first solution comprising an aqueous phase; b) obtaining a second solution comprising an organic phase and a plurality of molecules capable of self-assembly, wherein the first and second solutions are miscible; c) dissolving at least one payload molecule in either the first or second solution; d) preparing the phases having various compositions and dispensing them into a plurality of wells using a robotic liquid handler; and e) mixing the first and second solutions and using the robotic liquid handler under conditions suitable for LNP formation. A method for obtaining lipid nanoparticles for use in encapsulating the payload, wherein the following conditions are met: f. obtaining lipid nanoparticles in which at least one of the following varies between different wells: type of self-assembling molecule, composition ratio of the self-assembling molecule, ratio and / or concentration of the self-assembling molecule to the payload, phase, buffer type and pH selection, injection sequence, injection rate, mixing rate, volume, phase ratio, injection duration, and mixing duration; g. measuring at least one of the following: encapsulation efficiency, particle size distribution, purification and particle recovery rate, and formulation stability of the LNP; g. determining optimal parameters for producing the LNP preparation; and h. producing the LNP preparation based on the optimal parameters.
[0006] In various embodiments, the payload is an oligonucleotide. In various embodiments, the oligonucleotide is an antisense molecule. In various embodiments, the oligonucleotide is siRNA. In various embodiments, the oligonucleotide is shRNA. In various embodiments, the oligonucleotide is about 10 to about 30 nucleotides long. In various embodiments, the payload is mRNA. In various embodiments, the size of the mRNA is about 500 to 3000 nucleotides. In various embodiments, the payload is a polypeptide. In various embodiments, the polypeptide is about 1,000 Da to about 10,000 Da. In various embodiments, the payload is a small molecule. In various embodiments, the small molecule is about 100 Da to 1000 Da.
[0007] In various embodiments, the payload is dissolved in a first solution. In various embodiments, the payload is dissolved in a second solution. In various embodiments, the first solution is an aqueous buffer. In various embodiments, the first solution includes a pH-adjusted buffer and a weight-osmolality-adjusted buffer. In various embodiments, the organic phase of the second solution contains methanol. In various embodiments, the organic phase of the second solution contains ethanol.
[0008] In various embodiments, the self-assembling molecule comprises at least one lipid component consisting of at least one lipid molecule. In various embodiments, the at least one lipid molecule is selected from cationic or ionizable lipid species, non-cationic lipid species, and phospholipid species. In various embodiments, the second solution comprises two or more lipids. In various embodiments, the total lipid concentration varies. In various embodiments, the total lipid concentration varies between about 0.4 and about 4 mM. In various embodiments, the percentage of PEGylated lipids varies. In various embodiments, the percentage of PEGylated lipids varies between about 0.5% and about 5% of the total lipid composition. In various embodiments, the N:P ratio of the payload varies. In various embodiments, the N:P ratio varies between about 0.5 and about 5.
[0009] In various embodiments, LNPs are polymer lipid nanoparticles. In various embodiments, LNPs are liposomes. In various embodiments, LNPs are lipoprotein nanoparticles. In various embodiments, the first solution is injected into the second solution. In various embodiments, the second solution is injected into the first solution. In various embodiments, the optimal parameters are those that result in a payload encapsulation efficiency of over 80%. In various embodiments, the optimal parameters are those that result in LNPs having an average diameter of 80-200 nm, with a unimodal size distribution and polydispersity of less than about 30%. In various embodiments, the LNPs maintain a similar size distribution and payload encapsulation for at least one month under storage in solution at 4°C.
[0010] In various embodiments, the disclosure relates to a high-throughput method for optimizing a method for producing lipid nanoparticle (LNP) preparations, the method comprising: a) obtaining a first solution comprising an aqueous phase; b) obtaining a second solution comprising an organic phase and a plurality of self-assembling molecules, wherein the first and second solutions are miscible; c) dissolving at least one payload molecule in either the first or second solution; d) preparing the phases having various compositions and dispensing them into a plurality of wells using a robotic liquid handler; and e) mixing the first and second solutions and using the robotic liquid handler under conditions suitable for LNP formation. A method for obtaining lipid nanoparticles for encapsulating the payload, wherein the following conditions are met: f. obtaining lipid nanoparticles in which at least one of the following varies between different wells: type of self-assembling molecule, composition ratio of the self-assembling molecule, ratio and / or concentration of the self-assembling molecule to the payload, phase, buffer type and pH selection, injection sequence, injection rate, mixing rate, volume, phase ratio, injection duration, and mixing duration; g. measuring at least one of the following: encapsulation efficiency, particle size distribution, purification and particle recovery rate, and formulation stability of the LNP; g. determining optimal parameters for producing the LNP preparation; and h. producing the LNP preparation based on the optimal parameters.
[0011] In various embodiments, the payload is an oligonucleotide. In various embodiments, the oligonucleotide is an antisense molecule. In various embodiments, the oligonucleotide is siRNA. In various embodiments, the oligonucleotide is shRNA. In various embodiments, the oligonucleotide is about 10 to about 30 nucleotides long. In various embodiments, the payload is mRNA. In various embodiments, the size of the mRNA is about 1 kb to about 2 kb. In various embodiments, the payload is a polypeptide. In various embodiments, the polypeptide is about 1,000 Da to about 10,000 Da. In various embodiments, the payload is a small molecule. In various embodiments, the small molecule is about 100 Da to 1,000 Da.
[0012] In various embodiments, the payload is dissolved in a first solution. In various embodiments, the payload is dissolved in a second solution. In various embodiments, the first solution is an aqueous buffer. In various embodiments, the first solution includes a pH-adjusted buffer and a weight-osmolality-adjusted buffer. In various embodiments, the organic phase of the second solution contains methanol. In various embodiments, the organic phase of the second solution contains ethanol.
[0013] In various embodiments, the self-assembling molecule comprises at least one lipid component composed of at least one lipid molecule. In various embodiments, the at least one lipid molecule is selected from cationic lipid species, non-cationic lipid species, and phospholipid species. In various embodiments, the second solution comprises two or more lipids. In various embodiments, the total lipid concentration varies. In various embodiments, the total lipid concentration varies between about 0.4 and about 4 mM. In various embodiments, the percentage of PEGylated lipids varies. In various embodiments, the percentage of PEGylated lipids varies between about 0.5% and about 5% of the total lipid composition. In various embodiments, the N:P ratio of the payload varies. In various embodiments, the N:P ratio varies between about 0.5 and about 5.
[0014] In various embodiments, LNPs are polymer lipid nanoparticles. In various embodiments, LNPs are liposomes. In various embodiments, LNPs are lipoprotein nanoparticles. In various embodiments, the first solution is injected into the second solution. In various embodiments, the second solution is injected into the first solution. In various embodiments, the optimal parameters are those that result in a payload encapsulation efficiency of over 80%. In various embodiments, the optimal parameters are those that result in LNPs having an average diameter of 80-200 nm, with a unimodal size distribution and polydispersity of less than about 30%. In various embodiments, the LNPs maintain a similar size distribution and payload encapsulation for at least one month under storage in solution at 4°C.
[0015] In various embodiments, the disclosure relates to an optimized high-throughput method for encapsulating a payload in a lipid nanoparticle (LNP) preparation, the method comprising: a) obtaining a first solution comprising an aqueous phase; b) obtaining a second solution comprising an organic phase and a plurality of self-assembling molecules, wherein the first and second solutions are miscible; c) dissolving at least one payload molecule in either the first or second solution; d) preparing the phases having various compositions and dispensing them into a plurality of wells using a robotic liquid handler; and e) mixing the first and second solutions and using the robotic liquid handler under conditions suitable for LNP formation. A method for obtaining lipid nanoparticles for use in encapsulating the payload, wherein the following conditions are met: f. obtaining lipid nanoparticles in which at least one of the following varies between different wells: type of self-assembling molecule, composition ratio of the self-assembling molecule, ratio and / or concentration of the self-assembling molecule to the payload, phase, buffer type and pH selection, injection sequence, injection rate, mixing rate, volume, phase ratio, injection duration, and mixing duration; g. measuring at least one of the following: encapsulation efficiency, particle size distribution, purification and particle recovery rate, and formulation stability of the LNP; g. determining optimal parameters for producing the LNP preparation; and h. producing the LNP preparation based on the optimal parameters.
[0016] In various embodiments, the payload is an oligonucleotide. In various embodiments, the oligonucleotide is an antisense molecule. In various embodiments, the oligonucleotide is siRNA. In various embodiments, the oligonucleotide is shRNA. In various embodiments, the oligonucleotide is about 10 to about 30 nucleotides long. In various embodiments, the payload is mRNA. In various embodiments, the size of the mRNA is about 1 kb to about 2 kb. In various embodiments, the payload is a polypeptide. In various embodiments, the polypeptide is about 1,000 Da to about 10,000 Da. In various embodiments, the payload is a small molecule. In various embodiments, the small molecule is about 100 Da to 1,000 Da.
[0017] In various embodiments, the payload is dissolved in a first solution. In various embodiments, the payload is dissolved in a second solution. In various embodiments, the first solution is an aqueous buffer. In various embodiments, the first solution includes a pH-adjusted buffer and a weight-osmolality-adjusted buffer. In various embodiments, the organic phase of the second solution contains methanol. In various embodiments, the organic phase of the second solution contains ethanol.
[0018] In various embodiments, the self-assembling molecule comprises at least one lipid component composed of at least one lipid molecule. In various embodiments, the at least one lipid molecule is selected from cationic lipid species, non-cationic lipid species, and phospholipid species. In various embodiments, the second solution comprises two or more lipids. In various embodiments, the total lipid concentration varies. In various embodiments, the total lipid concentration varies between about 0.4 and about 4 mM. In various embodiments, the percentage of PEGylated lipids varies. In various embodiments, the percentage of PEGylated lipids varies between about 0.5% and about 5% of the total lipid composition. In various embodiments, the N:P ratio of the payload varies. In various embodiments, the N:P ratio varies between about 0.5 and about 5.
[0019] In various embodiments, LNPs are polymer lipid nanoparticles. In various embodiments, LNPs are liposomes. In various embodiments, LNPs are lipoprotein nanoparticles. In various embodiments, the first solution is injected into the second solution. In various embodiments, the second solution is injected into the first solution. In various embodiments, the optimal parameters are those that result in a payload encapsulation efficiency of over 80%. In various embodiments, the optimal parameters are those that result in LNPs having an average diameter of 80-200 nm, with a unimodal size distribution and polydispersity of less than about 30%. In various embodiments, the LNPs maintain a similar size distribution and payload encapsulation for at least one month under storage in solution at 4°C.
[0020] In various embodiments, the Disclosure relates to a method for administering an LNP preparation to a patient in need thereof, wherein the LNP preparation comprises: a. obtaining a first solution comprising an aqueous phase; b. obtaining a second solution comprising an organic phase and a plurality of molecules capable of self-assembling, wherein the first and second solutions are miscible; c. dissolving at least one payload molecule in either the first or second solution; d. preparing the phases having various compositions and dispensing them into a plurality of wells using a robotic liquid handler; e. mixing the first and second solutions and dispensing them into the payload using the robotic liquid handler under conditions suitable for LNP formation. The present invention provides for obtaining lipid nanoparticles for encapsulating LNPs, wherein the following conditions are met: f. obtaining lipid nanoparticles in which at least one of the following varies between different wells: type of self-assembling molecule, composition ratio of the self-assembling molecule, ratio and / or concentration of the self-assembling molecule to the payload, phase, buffer type and pH selection, injection sequence, injection rate, mixing rate, volume, phase ratio, injection duration, and mixing duration; f. measuring at least one of the following: encapsulation efficiency, particle size distribution, purification and particle recovery rate, and formulation stability of the LNPs; g. determining optimal parameters for producing the LNP preparation; and h. producing the LNP preparation based on the optimal parameters.
[0021] In various embodiments, the payload is an oligonucleotide. In various embodiments, the oligonucleotide is an antisense molecule. In various embodiments, the oligonucleotide is siRNA. In various embodiments, the oligonucleotide is shRNA. In various embodiments, the oligonucleotide is about 10 to about 30 nucleotides in length. In various embodiments, the payload is mRNA. In various embodiments, the size of the mRNA is about 1 kb to about 2 kb. In various embodiments, the payload is a polypeptide. In various embodiments, the polypeptide is about 1,000 Da to about 10,000 Da. In various embodiments, the payload is a small molecule. In various embodiments, the small molecule is about 100 Da to 1000 Da.
[0022] In various embodiments, the payload is dissolved in a first solution. In various embodiments, the payload is dissolved in a second solution. In various embodiments, the first solution is an aqueous buffer. In various embodiments, the first solution includes a pH-adjusted buffer and an osmolality-adjusted buffer. In various embodiments, the organic phase of the second solution includes methanol. In various embodiments, the organic phase of the second solution includes ethanol.
[0023] In various embodiments, the self-assembling molecule includes at least one lipid component composed of at least one type of lipid molecule. In various embodiments, the at least one type of lipid molecule is selected from cationic lipid species, non-cationic lipid species, and phospholipid species. In various embodiments, the second solution includes two or more types of lipids. In various embodiments, the total lipid concentration varies. In various embodiments, the total lipid concentration varies between about 0.4 and about 4 mM. In various embodiments, the percentage of PEGylated lipid varies. In various embodiments, the percentage of PEGylated lipid varies between about 0.5% and about 5% of the total lipid composition. In various embodiments, the N:P ratio of the payload varies. In various embodiments, the N:P ratio varies between about 0.5 and about 5.
[0024] In various embodiments, the LNP is a polymeric lipid nanoparticle. In various embodiments, the LNP is a liposome. In various embodiments, the LNP is a lipoprotein nanoparticle. In various embodiments, the first solution is injected into the second solution. In various embodiments, the second solution is injected into the first solution. In various embodiments, the optimal parameters are those that result in an encapsulation efficiency of the payload exceeding 80%. In various embodiments, the optimal parameters are those that result in an LNP having a unimodal size distribution and a polydispersity of less than about 30% and an average diameter of 80 - 200 nm. In various embodiments, the LNP maintains a similar size distribution and payload encapsulation for at least one month upon storage in a solution at 4°C.
[0025] In various embodiments, the disclosure relates to an optimized high-throughput method for encapsulating a payload in a lipid nanoparticle (LNP) preparation, the method comprising: a) obtaining a first solution comprising an aqueous phase; b) obtaining a second solution comprising an organic phase and a plurality of self-assembling molecules, wherein the first and second solutions are miscible; c) dissolving at least one payload molecule in either the first or second solution; d) preparing the phases having various compositions and dispensing them into a plurality of wells using a robotic liquid handler; and e) mixing the first and second solutions and using the robotic liquid handler under conditions suitable for LNP formation. A method for obtaining lipid nanoparticles for use in encapsulating the payload, wherein the following conditions are met: f. obtaining lipid nanoparticles in which at least one of the following varies between different wells: type of self-assembling molecule, composition ratio of the self-assembling molecule, ratio and / or concentration of the self-assembling molecule to the payload, phase, buffer type and pH selection, injection sequence, injection rate, mixing rate, volume, phase ratio, injection duration, and mixing duration; g. measuring at least one of the following: encapsulation efficiency, particle size distribution, purification and particle recovery rate, and formulation stability of the LNP; g. determining optimal parameters for producing the LNP preparation; and h. producing the LNP preparation based on the optimal parameters.
[0026] In various embodiments, the payload is an oligonucleotide. In various embodiments, the oligonucleotide is an antisense molecule. In various embodiments, the oligonucleotide is siRNA. In various embodiments, the oligonucleotide is shRNA. In various embodiments, the oligonucleotide is about 10 to about 30 nucleotides long. In various embodiments, the payload is mRNA. In various embodiments, the size of the mRNA is about 1 kb to about 2 kb. In various embodiments, the payload is a polypeptide. In various embodiments, the polypeptide is about 1,000 Da to about 10,000 Da. In various embodiments, the payload is a small molecule. In various embodiments, the small molecule is about 100 Da to 1,000 Da.
[0027] In various embodiments, the payload is dissolved in a first solution. In various embodiments, the payload is dissolved in a second solution. In various embodiments, the first solution is an aqueous buffer. In various embodiments, the first solution includes a pH-adjusted buffer and a weight-osmolality-adjusted buffer. In various embodiments, the organic phase of the second solution contains methanol. In various embodiments, the organic phase of the second solution contains ethanol.
[0028] In various embodiments, the self-assembling molecule comprises at least one lipid component composed of at least one lipid molecule. In various embodiments, the at least one lipid molecule is selected from cationic lipid species, non-cationic lipid species, and phospholipid species. In various embodiments, the second solution comprises two or more lipids. In various embodiments, the total lipid concentration varies. In various embodiments, the total lipid concentration varies between about 0.4 and about 4 mM. In various embodiments, the percentage of PEGylated lipids varies. In various embodiments, the percentage of PEGylated lipids varies between about 0.5% and about 5% of the total lipid composition. In various embodiments, the N:P ratio of the payload varies. In various embodiments, the N:P ratio varies between about 0.5 and about 5.
[0029] In various embodiments, LNPs are polymer lipid nanoparticles. In various embodiments, LNPs are liposomes. In various embodiments, LNPs are lipoprotein nanoparticles. In various embodiments, the first solution is injected into the second solution. In various embodiments, the second solution is injected into the first solution. In various embodiments, the optimal parameters are those that result in a payload encapsulation efficiency of over 80%. In various embodiments, the optimal parameters are those that result in LNPs having an average diameter of 80-200 nm, with a unimodal size distribution and polydispersity of less than about 30%. In various embodiments, the LNPs maintain a similar size distribution and payload encapsulation for at least one month under storage in solution at 4°C.
[0030] In various embodiments, the disclosure relates to an optimized high-throughput screening method for producing lipid nanoparticle (LNP) preparations, the method comprising: a) obtaining a first solution comprising an aqueous phase; b) obtaining a second solution comprising an organic phase and a plurality of molecules capable of self-assembly, wherein the first and second solutions are miscible; c) dissolving at least one payload molecule in either the first or second solution; d) preparing the phases having various compositions and dispensing them into a plurality of wells using a robotic liquid handler; and e) mixing the first and second solutions and using the robotic liquid handler under conditions suitable for LNP formation. A method for obtaining lipid nanoparticles for use in encapsulating the payload, wherein the following conditions are met: f. obtaining lipid nanoparticles in which at least one of the following varies between different wells: type of self-assembling molecule, composition ratio of the self-assembling molecule, ratio and / or concentration of the self-assembling molecule to the payload, phase, buffer type and pH selection, injection sequence, injection rate, mixing rate, volume, phase ratio, injection duration, and mixing duration; g. measuring at least one of the following: encapsulation efficiency, particle size distribution, purification and particle recovery rate, and formulation stability of the LNP; g. determining optimal parameters for producing the LNP preparation; and h. producing the LNP preparation based on the optimal parameters.
[0031] In various embodiments, the payload is an oligonucleotide. In various embodiments, the oligonucleotide is an antisense molecule. In various embodiments, the oligonucleotide is siRNA. In various embodiments, the oligonucleotide is shRNA. In various embodiments, the oligonucleotide is about 10 to about 30 nucleotides long. In various embodiments, the payload is mRNA. In various embodiments, the size of the mRNA is about 1 kb to about 2 kb. In various embodiments, the payload is a polypeptide. In various embodiments, the polypeptide is about 1,000 Da to about 10,000 Da. In various embodiments, the payload is a small molecule. In various embodiments, the small molecule is about 100 Da to 1,000 Da.
[0032] In various embodiments, the payload is dissolved in a first solution. In various embodiments, the payload is dissolved in a second solution. In various embodiments, the first solution is an aqueous buffer. In various embodiments, the first solution includes a pH-adjusted buffer and a weight-osmolality-adjusted buffer. In various embodiments, the organic phase of the second solution contains methanol. In various embodiments, the organic phase of the second solution contains ethanol.
[0033] In various embodiments, the self-assembling molecule comprises at least one lipid component composed of at least one lipid molecule. In various embodiments, the at least one lipid molecule is selected from cationic lipid species, non-cationic lipid species, and phospholipid species. In various embodiments, the second solution comprises two or more lipids. In various embodiments, the total lipid concentration varies. In various embodiments, the total lipid concentration varies between about 0.4 and about 4 mM. In various embodiments, the percentage of PEGylated lipids varies. In various embodiments, the percentage of PEGylated lipids varies between about 0.5% and about 5% of the total lipid composition. In various embodiments, the N:P ratio of the payload varies. In various embodiments, the N:P ratio varies between about 0.5 and about 5.
[0034] In various embodiments, LNPs are polymer lipid nanoparticles. In various embodiments, LNPs are liposomes. In various embodiments, LNPs are lipoprotein nanoparticles. In various embodiments, the first solution is injected into the second solution. In various embodiments, the second solution is injected into the first solution. In various embodiments, the optimal parameters are those that result in a payload encapsulation efficiency of over 80%. In various embodiments, the optimal parameters are those that result in LNPs having an average diameter of 80-200 nm, with a unimodal size distribution and polydispersity of less than about 30%. In various embodiments, the LNPs maintain a similar size distribution and payload encapsulation for at least one month under storage in solution at 4°C.
[0035] In various embodiments, the disclosure relates to an optimized high-throughput method for encapsulating a payload in a lipid nanoparticle (LNP) preparation, the method comprising: a) obtaining a first solution comprising an aqueous phase; b) obtaining a second solution comprising an organic phase and a plurality of self-assembling molecules, wherein the first and second solutions are miscible; c) dissolving at least one payload molecule in either the first or second solution; d) preparing the phases having various compositions and dispensing them into a plurality of wells using a robotic liquid handler; and e) mixing the first and second solutions and using the robotic liquid handler under conditions suitable for LNP formation. A method for obtaining lipid nanoparticles for use in encapsulating the payload, wherein the following conditions are met: f. obtaining lipid nanoparticles in which at least one of the following varies between different wells: type of self-assembling molecule, composition ratio of the self-assembling molecule, ratio and / or concentration of the self-assembling molecule to the payload, phase, buffer type and pH selection, injection sequence, injection rate, mixing rate, volume, phase ratio, injection duration, and mixing duration; g. measuring at least one of the following: encapsulation efficiency, particle size distribution, purification and particle recovery rate, and formulation stability of the LNP; g. determining optimal parameters for producing the LNP preparation; and h. producing the LNP preparation based on the optimal parameters.
[0036] In various embodiments, the payload is an oligonucleotide. In various embodiments, the oligonucleotide is an antisense molecule. In various embodiments, the oligonucleotide is siRNA. In various embodiments, the oligonucleotide is shRNA. In various embodiments, the oligonucleotide is about 10 to about 30 nucleotides long. In various embodiments, the payload is mRNA. In various embodiments, the size of the mRNA is about 1 kb to about 2 kb. In various embodiments, the payload is a polypeptide. In various embodiments, the polypeptide is about 1,000 Da to about 10,000 Da. In various embodiments, the payload is a small molecule. In various embodiments, the small molecule is about 100 Da to 1,000 Da.
[0037] In various embodiments, the payload is dissolved in a first solution. In various embodiments, the payload is dissolved in a second solution. In various embodiments, the first solution is an aqueous buffer. In various embodiments, the first solution includes a pH-adjusted buffer and a weight-osmolality-adjusted buffer. In various embodiments, the organic phase of the second solution contains methanol. In various embodiments, the organic phase of the second solution contains ethanol.
[0038] In various embodiments, the self-assembling molecule comprises at least one lipid component composed of at least one lipid molecule. In various embodiments, the at least one lipid molecule is selected from cationic lipid species, non-cationic lipid species, and phospholipid species. In various embodiments, the second solution comprises two or more lipids. In various embodiments, the total lipid concentration varies. In various embodiments, the total lipid concentration varies between about 0.4 and about 4 mM. In various embodiments, the percentage of PEGylated lipids varies. In various embodiments, the percentage of PEGylated lipids varies between about 0.5% and about 5% of the total lipid composition. In various embodiments, the N:P ratio of the payload varies. In various embodiments, the N:P ratio varies between about 0.5 and about 5.
[0039] In various embodiments, LNPs are polymer lipid nanoparticles. In various embodiments, LNPs are liposomes. In various embodiments, LNPs are lipoprotein nanoparticles. In various embodiments, the first solution is injected into the second solution. In various embodiments, the second solution is injected into the first solution. In various embodiments, the optimal parameters are those that result in a payload encapsulation efficiency of over 80%. In various embodiments, the optimal parameters are those that result in LNPs having an average diameter of 80-200 nm, with a unimodal size distribution and polydispersity of less than about 30%. In various embodiments, the LNPs maintain a similar size distribution and payload encapsulation for at least one month under storage in solution at 4°C.
[0040] In various embodiments, the disclosure provides a method comprising the following steps: a. obtaining a first solution comprising an aqueous phase; b. obtaining a second solution comprising an organic phase and a plurality of self-assembling molecules, wherein the first and second solutions are miscible; c. dissolving at least one payload molecule in either the first or second solution; d. preparing the phases having various compositions and dispensing them into a plurality of wells using a robotic liquid handler; e. mixing the first and second solutions to obtain lipid nanoparticles in which the payload is encapsulated using the robotic liquid handler under conditions suitable for LNP formation, wherein the conditions are: self The present invention relates to optimized lipid nanoparticles (LNPs) produced by a method comprising: f. obtaining lipid nanoparticles in which at least one of the following varies between different wells: the type of assembly molecule, the composition ratio of the self-assembling molecules, the ratio and / or concentration of the self-assembling molecules to the payload, the selection of phase, buffer type and pH, injection sequence, injection rate, mixing rate, volume, phase ratio, injection duration, and mixing duration; f. measuring at least one of the following: encapsulation efficiency, particle size distribution, purification and particle recovery rate, and formulation stability of the LNPs; g. determining optimal parameters for producing the LNP preparation; and h. producing the LNP preparation based on the optimal parameters.
[0041] In various embodiments, the payload is an oligonucleotide. In various embodiments, the oligonucleotide is an antisense molecule. In various embodiments, the oligonucleotide is siRNA. In various embodiments, the oligonucleotide is shRNA. In various embodiments, the oligonucleotide is about 10 to about 30 nucleotides long. In various embodiments, the payload is mRNA. In various embodiments, the size of the mRNA is about 1 kb to about 2 kb. In various embodiments, the payload is a polypeptide. In various embodiments, the polypeptide is about 1,000 Da to about 10,000 Da. In various embodiments, the payload is a small molecule. In various embodiments, the small molecule is about 100 Da to 1,000 Da.
[0042] In various embodiments, the payload is dissolved in a first solution. In various embodiments, the payload is dissolved in a second solution. In various embodiments, the first solution is an aqueous buffer. In various embodiments, the first solution includes a pH-adjusted buffer and a weight-osmolality-adjusted buffer. In various embodiments, the organic phase of the second solution contains methanol. In various embodiments, the organic phase of the second solution contains ethanol.
[0043] In various embodiments, the self-assembling molecule comprises at least one lipid component composed of at least one lipid molecule. In various embodiments, the at least one lipid molecule is selected from cationic lipid species, non-cationic lipid species, and phospholipid species. In various embodiments, the second solution comprises two or more lipids. In various embodiments, the total lipid concentration varies. In various embodiments, the total lipid concentration varies between about 0.4 and about 4 mM. In various embodiments, the percentage of PEGylated lipids varies. In various embodiments, the percentage of PEGylated lipids varies between about 0.5% and about 5% of the total lipid composition. In various embodiments, the N:P ratio of the payload varies. In various embodiments, the N:P ratio varies between about 0.5 and about 5.
[0044] In various embodiments, LNPs are polymer lipid nanoparticles. In various embodiments, LNPs are liposomes. In various embodiments, LNPs are lipoprotein nanoparticles. In various embodiments, the first solution is injected into the second solution. In various embodiments, the second solution is injected into the first solution. In various embodiments, the optimal parameters are those that result in a payload encapsulation efficiency of over 80%. In various embodiments, the optimal parameters are those that result in LNPs having an average diameter of 80-200 nm, with a unimodal size distribution and polydispersity of less than about 30%. In various embodiments, the LNPs maintain a similar size distribution and payload encapsulation for at least one month under storage in solution at 4°C.
[0045] In various embodiments, the disclosure relates to an optimized high-throughput method for encapsulating a payload in a lipid nanoparticle (LNP) preparation, the method comprising: a) obtaining a first solution comprising an aqueous phase; b) obtaining a second solution comprising an organic phase and a plurality of self-assembling molecules, wherein the first and second solutions are miscible; c) dissolving at least one payload molecule in either the first or second solution; d) preparing the phases having various compositions and dispensing them into a plurality of wells using a robotic liquid handler; and e) mixing the first and second solutions and using the robotic liquid handler under conditions suitable for LNP formation. A method for obtaining lipid nanoparticles for use in encapsulating the payload, wherein the following conditions are met: f. obtaining lipid nanoparticles in which at least one of the following varies between different wells: type of self-assembling molecule, composition ratio of the self-assembling molecule, ratio and / or concentration of the self-assembling molecule to the payload, phase, buffer type and pH selection, injection sequence, injection rate, mixing rate, volume, phase ratio, injection duration, and mixing duration; g. measuring at least one of the following: encapsulation efficiency, particle size distribution, purification and particle recovery rate, and formulation stability of the LNP; g. determining optimal parameters for producing the LNP preparation; and h. producing the LNP preparation based on the optimal parameters.
[0046] In various embodiments, the payload is an oligonucleotide. In various embodiments, the oligonucleotide is an antisense molecule. In various embodiments, the oligonucleotide is siRNA. In various embodiments, the oligonucleotide is shRNA. In various embodiments, the oligonucleotide is about 10 to about 30 nucleotides long. In various embodiments, the payload is mRNA. In various embodiments, the size of the mRNA is about 1 kb to about 2 kb. In various embodiments, the payload is a polypeptide. In various embodiments, the polypeptide is about 1,000 Da to about 10,000 Da. In various embodiments, the payload is a small molecule. In various embodiments, the small molecule is about 100 Da to 1,000 Da.
[0047] In various embodiments, the payload is dissolved in a first solution. In various embodiments, the payload is dissolved in a second solution. In various embodiments, the first solution is an aqueous buffer. In various embodiments, the first solution includes a pH-adjusted buffer and a weight-osmolality-adjusted buffer. In various embodiments, the organic phase of the second solution contains methanol. In various embodiments, the organic phase of the second solution contains ethanol.
[0048] In various embodiments, the self-assembling molecule comprises at least one lipid component composed of at least one lipid molecule. In various embodiments, the at least one lipid molecule is selected from cationic lipid species, non-cationic lipid species, and phospholipid species. In various embodiments, the second solution comprises two or more lipids. In various embodiments, the total lipid concentration varies. In various embodiments, the total lipid concentration varies between about 0.4 and about 4 mM. In various embodiments, the percentage of PEGylated lipids varies. In various embodiments, the percentage of PEGylated lipids varies between about 0.5% and about 5% of the total lipid composition. In various embodiments, the N:P ratio of the payload varies. In various embodiments, the N:P ratio varies between about 0.5 and about 5.
[0049] In various embodiments, LNPs are polymer lipid nanoparticles. In various embodiments, LNPs are liposomes. In various embodiments, LNPs are lipoprotein nanoparticles. In various embodiments, the first solution is injected into the second solution. In various embodiments, the second solution is injected into the first solution. In various embodiments, the optimal parameters are those that result in a payload encapsulation efficiency of over 80%. In various embodiments, the optimal parameters are those that result in LNPs having an average diameter of 80-200 nm, with a unimodal size distribution and polydispersity of less than about 30%. In various embodiments, the LNPs maintain a similar size distribution and payload encapsulation for at least one month under storage in solution at 4°C.
[0050] In various embodiments, the Disclosure relates to a workflow for HTS screening of multiple parameters for LNP formation, comprising: (i) a robotic liquid handler; (ii) at least one instrument capable of measuring desired LNP properties; and (iii) at least one microplate containing a plurality of microwells, wherein the robotic liquid handler can inject a plurality of solutions into each of the microwells; the parameters vary systematically between the microwells; and the desired LNP properties can be measured for each microwell.
[0051] In various embodiments, multiple parameters are selected from total lipid content; type of self-assembling molecule; composition ratio of the self-assembling molecule; ratio and / or concentration of the self-assembling molecule to the payload; selection of phase, buffer type and pH, injection sequence, volume and rate, and mixing duration. In various embodiments, the desired LNP properties are selected from the group consisting of average particle size, particle size distribution, encapsulation efficiency, and particle stability. In various embodiments, the instrument may be dynamic light scattering (DLS), ultraviolet-visible (UV-Vis) spectroscopy, or fluorescence spectroscopy. [Brief explanation of the drawing]
[0052] [Figure 1A-1F] This report presents data for highly ASO-loaded, homogeneous LNPs produced by high-speed ethanol-buffer injection followed by multiple mixings. LNPs consisting of 0.4 μmol of total lipids and 1.5 mol% DSPE-PEG2000 were mixed with ASO-1 under different mixing conditions at an N / P ratio of 1. Using a TECAN robot, reverse injection sequences (ethanol-buffer or buffer-ethanol) at rates of 0.1, 0.5, or 0.9 ml / s followed by 10 mixing iterations (Figures 1A-1C), or ethanol-buffer injection at rates of 0.5 or 0.9 ml / s followed by 10 or 20 mixing iterations (Figures 1D-1F) were investigated. Particle size (Figures 1A and 1D) and polydispersity (Figures 1B and 1E) were measured by dynamic light scattering (DLS). Free ASO-1 was measured by OD260, and encapsulation efficiency was calculated (Figures 1C and 1F). The results were mean ± SD, n=3; ns, not significant, ****P<0.0001. (Figures 1A-1C) Two-way or one-way (Figures 1D-1F) ANOVA, followed by Tukey's multiple comparison analysis.
[0053] [Figure 2] This document describes the HTS workflow for ASO-loaded LNP formulations. 96 samples (32 conditions, n=3) were prepared using an automated solvent injection method with TECAN® liquid handlers, varying in four levels of lipid composition, two levels of total lipid concentration, and four levels of ASO loading. Subsequently, DLS (Digital Leaving Saturation) at 260 nm and particle size distribution by ASO encapsulation were characterized. A typical LEA (Laboratory Execution and Analysis) Library Studio design layout for the sample plate is shown.
[0054] [Figure 3A-3E]This is an HTS analysis of ASO-1 loaded LNP formulations. Figure 3A shows the screening design. Formulation parameters, including total lipid concentration (2 levels), PEGylated lipid content incorporated into lipid composition (4 levels), and ASO loading ratio (4 levels), were screened in 96-well plates, with each condition repeated three times. Figures 3B-3D show that the samples were diluted with PBS and characterized for particle size distribution by DLS. Figure 3B is a graph showing a typical size distribution, indicating a population of small particles with increasing amounts of PEGylated lipids added to the lipid composition. Figures 3C-3D are heatmaps showing that LNPs had an average diameter of 45-145 nm and a %PD of 10-50%, excluding large aggregates (diameter of 500-1500 nm) with a multimodal size distribution when DSPE-PEG2000 was not incorporated into the lipid composition, as indicated by the black dots labeled "out of range". Quantitative analysis is also shown for samples with a total lipid concentration of 2 mM. Figure 3E is a bar graph showing sample aliquots (2 mM total lipid concentration) measured for the unencapsulated amount of ASO by OD260 to calculate encapsulation efficiency. Results were mean ± SD, n=3; ns, not significant, *P<0.05, **P<0.01, ***P<0.001, and ****P<0.0001 (analyzed by two-way ANOVA, followed by Tukey's multiple comparisons). This data was confirmed by LC.
[0055] [Figure 4] This bar graph shows that LNPs prepared without PEGylated lipids produced large aggregates. The mean particle size of ASO-1 loaded LNPs prepared without DSPE-PEG2000 (screened conditions are shown in columns A and E of Figures 3C-3D) is shown as mean ± SD, n=3; ns, not significant, *P<0.05, and ***P<0.001 (analyzed by two-way ANOVA followed by Sidak multiple comparisons).
[0056] [Figures 5A-5C]This is an HTS analysis of ASO-1 loaded cationic LNP formulations. The screened cationic LNPs showed similar trends to MC3 LNPs in terms of average diameter of 60–120 nm (Figure 5A), polydispersity of 10–50% (Figure 5B), and increase in the amount of PEGylated lipids. In the absence of DSPE-PEG2000, large aggregates with a multimodal size distribution were formed, as indicated by incomplete measurements (due to large aggregates) indicated by black or white dots labeled "out of range". Quantitative analysis is also shown for samples with a total lipid concentration of 2 mM (Figure 5C). The amount of unencapsulated ASO in the sample was measured by OD260, and the encapsulation efficiency was calculated. The results were mean ± SD, n=3; ns, not significant, *P<0.05, **P<0.01, ***P<0.001, and ****P<0.0001 (analysis by two-way ANOVA, followed by Tukey (Figures 5A-5B) or Sidak (Figure 5C) multiple comparisons).
[0057] [Figure 6A-6C] HTS analysis of ionizable lipids and formulated ASO-2 loaded LNPs under 2 mM total lipid concentration, different amounts of DSPE-PEG2000, and different oligonucleotide loading conditions. The results showed similar trends to ASO-1 loaded LNPs (Figures 3A-3E) with respect to ASO particle size (Figure 6A), polydispersity (Figure 6B), and encapsulation efficiency (Figure 6C). Results were mean ± SD, n=3; ns, not significant, *P<0.05, **P<0.01, ***P<0.001, and ****P<0.0001 (analyzed by two-way ANOVA, followed by Tukey's multiple comparisons).
[0058] [Figures 7A-7E]These are HTS analysis results correlated with results from microfluidic preparation using NanoAssemblr®. Figure 7A is a graph showing the correlation between decreasing particle size and increasing polydispersity with increasing PEGylated lipid content. LNPs were prepared with DSPE-PEG2000 at different molar ratios and a fixed N / P ratio of 2. Figure 7B is a graph showing that particle size was stable under high total lipid concentrations. LNPs were prepared under total lipid concentrations of 0.4, 0.7, 1, or 2 mM, 1.5 mol% fixed DSPE-PEG2000, and an N / P ratio of 2. Figures 7C-7D show that particle size (Figure 7C) was stable, while the %EE of ASO (Figure 7D) decreased under high and excessive ASO loading. LNPs were prepared under N / P ratios of 5, 2, 1, or 0.5 and 1.5 mol% DSPE-PEG2000. Figure 7E shows representative cryo-TEM images of ASO-1 loaded LNPs prepared by nanoassembly or high-throughput solvent injection using different formulation parameters. The enlarged image shows similar structural patterns of representative LNPs (indicated by blue arrows) prepared with the same formulation parameters using the two approaches. The HTS results in the panel (Figures 7A, 7C, 7D) are from the same screening experiment shown in Figure 3. The results are mean ± SD, with n=3 except for n=1 for the microfluidic results in Figure 7D.
[0059] [Figure 8A-8B] This study demonstrates the 2-week stability at 4°C of ASO-1 loaded MC3 LNPs prepared by high-throughput solvent injection or NanoAssemblr®. Figure 8A shows the average particle size, and Figure 8B is a graph showing polydispersity over 2 weeks. The total lipid concentration was 2 mM, the N / P ratio was 1 (HTS sample) or 0.5 (NanoAssemblr® sample), and the PEG content varied from 1.5 to 5 mol%. Results are mean ± SD, n=3; *P<0.05 and **P<0.01 vs. day 0 results for each group (analyzed by one-way ANOVA, followed by Dunnett's multiple comparison). Subsequent studies (not shown) showed similar results after 1 month of storage at 4°C.
[0060] [Figure 9] Figures 8A-8B show graphs illustrating the stability of HTS LNP at 40°C over two weeks. Results are in mean ± SD, n=3; *P<0.05 vs. day 0 results for each group (analyzed by one-way ANOVA, followed by Dunnett's multiple comparisons).
[0061] [Figure 10] This graph shows ASO leakage from LNPs at 40°C. ASO-1 released from LNPs within two weeks was measured by OD260. The results were mean ± SD, n=3; *P<0.05 and ns, not significant compared to the 1.5mol% DSPE-PEG2000 group (analyzed by two-way ANOVA followed by Turkey's multiple comparison).
[0062] [Figure 11] This study demonstrates that the HTS approach significantly reduces raw material consumption and improves analytical output compared to microfluidic preparation of ASO-loaded LNPs. Required materials were calculated for a typical sample containing 1.5 mol% DSPE-PEG 2000 and 2 mM total lipids with an N / P ratio (based on MC3 and ASO-1) of 1.
[0063] [Figures 12A-12B] An alternative method for quantifying ASO encapsulation is presented. Figure 12A is a schematic diagram of the workflow. ASO-loaded LNPs were prepared by high-throughput solvent injection, mixed with the fluorescent probe Sybr-gold, and subsequently quantified using a fluorescence plate reader (Ex / Em = 495 / 550 nm). Figure 12B is a graph showing equivalent encapsulation efficiency % for two different LNP formulations prepared under different N / P ratios. Results are mean ± SD, n=2;ns, not significant.
[0064] [Figure 13A]This paper describes the high-throughput filtration (HTS) workflow for HiBiT peptide-loaded liposome formulations. Two purification methods, including high-throughput gel filtration and dialysis in a 96-well plate format, were compared. LNPs were synthesized by high-throughput solvent injection, followed by characterization of particle size distribution by DLS and free cargo volume by UV-Vis, emission, and fluorescence. Subsequently, the LNPs were purified using either high-throughput gel filtration or dialysis, and then analyzed for purification efficiency, particle recovery, and particle size stability using UV-Vis, fluorescence, and DLS, respectively.
[0065] [Figure 13B] This image shows the screening design. Formulation parameters including DPPC LNP without MC3, DPPC LNP with MC3, DSPC LNP without MC3, and DSPC LNP containing MC3 that includes both apposited pegylated lipids conjugated with azide and pegylated lipids were screened in 3-row 96-well plates for each condition.
[0066] [Figure 13C] This heatmap shows that, excluding large aggregates with a multimodal size distribution when DSPE-PEG2000 was not incorporated into the lipid composition (indicated by the black dots outside the "range"), the LNPs had an average diameter of 50-200 nm.
[0067] [Figures 13D-13F] This table shows the quantitative determination of free peptide concentrations before (Figure 13D) and after purification. Gel filtration and dialysis yielded average purification efficiencies of approximately 98% (Figure 13E) and 61% (Figure 13F), respectively. A small 96-well column plate with 40kD MWCO was used for gel filtration and elution with PBS. A 96-well dialysis plate with 10kD MWCO was used overnight for dialysis in 3L PBS, with three medium changes. The loss of data points after dialysis was due to low sample recovery.
[0068] [Figure 13G-13H]These are data showing the quantification of particle recovery rate and size after purification by gel filtration. (Figure 13G) Recovery rates were generally between 80 and 120%, with the exception of low values for aggregated samples prepared without pegylated lipids. (Figure 13H) The particle size distribution remained constant even after purification by gel filtration. [Modes for carrying out the invention]
[0069] Detailed explanation The production of lipid nanoparticles (LNPs) for drug delivery is challenging due to their complex physicochemical properties, which are affected by various formulation parameters. Controlling particle structure and size distribution, physicochemical properties of the particle surface, lipid content, amount and encapsulation efficiency of free APIs, and physical and chemical stability in LNP production is difficult and complex. Screening LNP formulation parameters, including lipid species, percentage, concentration, and drug load, using conventional batch methods requires considerable time and raw materials. Therefore, a high-throughput screening approach with minimal material input and efficient preparation and analysis output would be preferable for determining lead formulation candidates with optimal quality attributes. Robotic liquid handlers are primarily used for liquid addition and transfer and are not used as LNP formulation devices with precisely tuned instrument parameters. Furthermore, there is a lack of streamlined high-throughput workflows integrating both LNP preparation and analysis. This specification provides a high-throughput method for optimizing LNP production based on desired properties using a robotic liquid handler for injection-based LNP formation. Optimized LNP particles and methods for producing them are further provided herein.
[0070] It should be understood that the description herein is illustrative and descriptive only and does not limit the claimed invention. In this application, unless otherwise specified, the use of the singular includes the plural.
[0071] Any headings used herein are for structural purposes only and should not be construed as limiting the subject matter described herein. All documents, or parts thereof (patents, patent applications, articles, books, and papers) cited herein are expressly incorporated herein by reference in whole for any purpose. When used in accordance with this disclosure, the following terms should be understood to have the following meanings unless otherwise indicated.
[0072] In this application, the use of “or” means “and / or” unless otherwise specified. Furthermore, the use of the term “including,” as well as other forms such as “includes” and “included,” is not limited. Also, terms such as “element” or “component” include both elements and components containing one unit and elements and components containing more than one subunit, unless otherwise specified.
[0073] As used herein, the term “subject” refers to any animal (e.g., mammal), including but not limited to humans, non-human primates, rodents, etc., that is a recipient of a particular procedure. Typically, the terms “subject” and “patient” are used interchangeably herein with respect to human subjects.
[0074] The terms "polynucleotide," "nucleotide," or "nucleic acid" include both single-stranded and double-stranded nucleotide polymers. Nucleotides containing polynucleotides may be ribonucleotides, deoxyribonucleotides, or modified forms of either type of nucleotide. Examples of such modifications include base modifications such as bromouridine and inosine derivatives, ribose modifications such as 2',3'-dideoxyribose, and internucleotide bond modifications such as phosphorothioates, phosphorodithioates, phosphoroselenoates, phosphorodiselenoates, phosphoranilothioates, phosphoraniladetes, and phosphoramidates.
[0075] The term "oligonucleotide" refers to a polynucleotide containing 200 or fewer nucleotides. Oligonucleotides can be single-stranded or double-stranded, for example, for use in constructing mutant genes. Oligonucleotides can be sense oligonucleotides or antisense oligonucleotides. Oligonucleotides can be labeled, including radioactive labels, fluorescent labels, hapten labels, or antigen labels, for detection assays. Oligonucleotides can be used, for example, as PCR primers, cloning primers, or hybridization probes.
[0076] The terms “polypeptide” or “protein” refer to macromolecules having an amino acid sequence of a protein, including the deletion, addition, and / or substitution of one or more amino acids from the natural sequence. The terms “polypeptide” and “protein” particularly encompass antigen-binding molecules, antibodies, or sequences having the deletion, addition, and / or substitution of one or more amino acids from an antigen-binding protein. The term “polypeptide fragment” refers to a polypeptide having amino-terminal deletions, carboxyl-terminal deletions, and / or internal deletions compared to a full-length natural protein. Such fragments may also contain modified amino acids compared to the natural protein. Useful polypeptide fragments include immunologically functional fragments of antigen-binding molecules.
[0077] The term “isolated” means (i) it does not contain at least some other proteins that are normally found; (ii) it does not contain other proteins from the same source, e.g., from the same species; (iii) it is isolated from at least about 50% of the polynucleotides, lipids, carbohydrates, or other material that are related in nature; (iv) it is operably related (by covalent or non-covalent interactions) with polypeptides that are not related in nature; or (v) it does not exist in nature.
[0078] A "variant" of a polypeptide (e.g., an antigen-binding molecule) includes an amino acid sequence in which one or more amino acid residues are inserted, deleted, and / or substituted compared to another polypeptide sequence. Variants include, for example, fusion proteins.
[0079] The term "identity" refers to the relationship between the sequences of two or more polypeptide molecules or two or more nucleic acid molecules, determined by aligning and comparing their sequences. "Identity percentage" means the percentage of identical residues between amino acids or nucleotides in the molecules being compared, and is calculated based on the smallest size of the molecules being compared. For these calculations, any gaps in the alignment (if any) are preferably addressed by a specific mathematical model or computer program (i.e., an "algorithm").
[0080] To calculate the percentage of identity, the sequences being compared are typically aligned to give the maximum match between them. An example of a computer program that can be used to determine the percentage of identity is the GCG program package, which includes GAP (Devereux et al., Nucl. Acid Res., 1984, 12, 387; Genetics Computer Group, University of Wisconsin, Madison, Wis.). The computer algorithm GAP is used to align two polypeptides or polynucleotides whose percentage sequence identity is determined. The sequences are aligned for the best possible matching of their respective amino acids or nucleotides (a "match span" determined by the algorithm). In certain embodiments, standard comparison matrices are also used by the algorithm (for example, see Dayhoff et al., 1978, Atlas of Protein Sequence and Structure, 5:345-352 for the PAM 250 comparison matrix; see Henikoff et al., 1992, Proc. Natl. Acad. Sci. USA, 89, 10915-10919 for the BLO-SUM 62 comparison matrix).
[0081] The term "derivative" refers to a molecule that includes chemical modifications other than the insertion, deletion, or substitution of amino acids (or nucleic acids). In certain embodiments, derivatives include covalent modifications, including chemical bonding with polymers, lipids, or other organic or inorganic moieties, but are not limited. In certain embodiments, chemically modified antigen-binding molecules may have a longer cyclic half-life than chemically modified antigen-binding molecules. In some embodiments, derivative antigen-binding molecules are covalently modified to include the attachment of one or more water-soluble polymers, including, but not limited to, polyethylene glycol, polyoxyethylene glycol, or polypropylene glycol.
[0082] Peptide analogs are commonly used in the pharmaceutical industry as non-peptide drugs that possess properties similar to those of a template peptide. These types of non-peptide compounds are called "peptide mimes" or "peptide mimes." Incorporated herein by reference for any purpose, Fauchere, JL, 1986, Adv. Drug Res., 1986, 15, 29; Veber, DF & Freidinger, RM, 1985, Trends in Neuroscience, 8, 392-396; and Evans, BE, et al., 1987, J. Med. Chem., 30, 1229-1239.
[0083] The term "therapeutic dose" refers to the amount of immune cells or other therapeutic agent determined to produce a therapeutic response in a mammal. Such a therapeutic dose is readily verifiable by those skilled in the art.
[0084] The terms “patient” and “subject” are used interchangeably and include human and non-human animal subjects, as well as subjects with formally diagnosed disabilities, subjects without formally recognized disabilities, subjects receiving medical attention, and subjects at risk of developing disabilities.
[0085] The terms “treat” and “treatment” include therapeutic treatments, preventive treatments, and applications that reduce the risk of a subject developing a disorder or other risk factors. Treatment does not require complete cure of the disorder and includes embodiments that mitigate symptoms or underlying risk factors. The term “prevent” does not require 100% elimination of the possibility of an event. Rather, it indicates that the likelihood of the event occurring is reduced in the presence of the compound or method.
[0086] Standard techniques can be used for recombinant DNA and oligonucleotide synthesis, as well as for tissue culture and transformation (e.g., electroporation, lipofection). Enzymatic reactions and purification techniques can be carried out according to the manufacturer's specifications, as commonly achieved in the art, or as described herein. The aforementioned techniques and procedures can generally be carried out according to conventional methods well known in the art, as described in the various general and more specific references cited and discussed herein. See, for example, Sambrook et al., Molecular Cloning: A Laboratory Manual (2nd ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY (1989)), incorporated herein by reference for any purpose.
[0087] As used herein, the terms “substantially” or “essentially” refer to a quantity, level, value, number, frequency, percentage, dimension, size, volume, weight, or length that is about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% higher than a reference quantity, level, value, number, frequency, percentage, dimension, size, volume, weight, or length. In one embodiment, the terms “essentially the same” or “substantially the same” refer to a range of quantities, levels, values, numbers, frequencies, percentages, dimensions, size, volume, weight, or length that is approximately the same as a reference quantity, level, value, number, frequency, percentage, dimension, size, volume, weight, or length.
[0088] As used herein, the terms “substantially absent” and “essentially absent” are interchangeable and, when used to describe compositions such as cell populations or culture media, refer to compositions that do not contain a particular substance, for example, 95% absent, 96% absent, 97% absent, 98% absent, 99% absent, or undetectable by conventional means. A similar meaning can be applied to the term “absence” which refers to the absence of a particular substance or component in a composition.
[0089] As used herein, the term “recognizable” means an event that is readily detectable by one or more standard methods, such as a quantity, level, value, number, frequency, percentage, dimension, size, quantity, weight, or length range. The terms “unrecognizable” and “not recognizable” and their equivalents mean an event that is not readily detectable or undetectable by standard methods, such as a quantity, level, value, number, frequency, percentage, dimension, size, quantity, weight, or length range. In one embodiment, an event is unrecognizable if it occurs at a rate of 5%, 4%, 3%, 2%, 1%, 0.1%, 0.001%, or less.
[0090] Throughout this specification, unless otherwise specified by context, the terms “comprise,” “comprises,” and “comprising” are understood to mean that they include the described process or element or group of processes or elements, but do not exclude any other process or element or group of processes or elements. In certain embodiments, the terms “include,” “has,” “contains,” and “comprise” are used synonymously.
[0091] As used herein, "consisting of" means including and being limited to what follows the phrase "consisting of." Therefore, the phrase "consisting of" indicates that the enumerated elements are necessary or essential, and that other elements cannot be present.
[0092] "Consisting essentially of" means including any elements listed after the phrase, but limited to other elements that do not interfere with or contribute to the activity or action of the listed elements as specified in this disclosure. Thus, the phrase "consisting essentially of" indicates that the listed elements are necessary or essential, but the other elements are not optional and may or may not be present, depending on whether they affect the activity or action of the listed elements.
[0093] Throughout this specification, references to “one embodiment,” “embodiment,” “specific embodiment,” “related embodiment,” “specific embodiment,” “additional embodiment,” or “further embodiment,” or any combination thereof, mean that the specific features, structures, or characteristics described in relation to the embodiment are included in at least one embodiment of the present invention. Therefore, occurrences of the aforementioned terms in various parts of this specification do not necessarily all refer to the same embodiment. Furthermore, specific features, structures, or characteristics can be combined in any suitable manner in one or more embodiments.
[0094] As used herein, the terms “about” or “approximately” refer to a quantity, level, value, number, frequency, percentage, dimension, size, volume, weight, or length that varies by 30, 25, 20, 15, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1% relative to a baseline quantity, level, value, number, frequency, percentage, dimension, size, volume, weight, or length. In certain embodiments, when the terms “about” or “approximately” precede a numerical value, they refer to a range of 15%, 10%, 5%, or 1%, or any intermediate range therein plus or minus.
[0095] High-throughput screening method for optimizing the production of lipid nanoparticles To address the need for screening and optimization of lipid-based nanopharmaceuticals, the disclosure herein provides a high-throughput screening (HTS) workflow for the preparation of lipid nanoparticles and for characterizing their particle size distribution and payload encapsulation.
[0096] In various embodiments, this disclosure relates to a high-throughput screening method for optimizing the production of lipid nanoparticles (LNPs). In various embodiments, the method disclosed herein utilizes a high-throughput screening (HTS) screening workflow comprising (i) a robotic liquid handler, (ii) at least one instrument capable of measuring desired LNP properties, and (iii) at least one microplate containing a plurality of microwells. In various embodiments, the LNPs are formed by the above HTS screening workflow using a solvent injection method. See, for example, Gentine et al., 2012, J Liposome Res. 22, 18-30; Schubert and Muller-Goymann, 2003, Eur. J. Pharm. Biopharm. 55, 125-131.
[0097] In various embodiments, the HTS workflow includes instruments capable of measuring desired LNP properties. Such properties include encapsulation efficiency, average particle size, and particle size distribution. Physical stability can also be determined by measuring particle size and payload release at different points in time after storage. Such analytical techniques are known in the art and include scanning / transmission electron microscopy (SEM / TEM), atomic force microscopy (AFM), ultracentrifugation (AUC), dynamic light scattering (DLS), ultraviolet (UV) spectroscopy, and flow field fractionation (FFF). In various embodiments, the HTS workflow includes instruments capable of DLS, UV-Vis, or fluorescence spectroscopy. In various embodiments, the methods disclosed herein utilize a high-throughput screening (HTS) screening workflow comprising (i) a robotic liquid handler, (ii) an instrument capable of performing DLS, (iii) an instrument capable of UV-Vis or fluorescence spectroscopy on a sample, and (iv) at least one microplate containing a plurality of microwells.
[0098] In various embodiments, the HTS workflow provides a method for optimizing LNP production using a solvent injection system. As used herein, “solvent injection system” means rapidly injecting a first solution containing lipid-containing self-assembling molecules into a second solution. In various embodiments, the solutions are miscible or miscible. In various embodiments, the first solution is a water-miscible solvent. In various embodiments, at least one solution is an organic phase solvent. Acetone, ethanol, isopropanol, and methanol are all suitable solvents for LNP preparation. In various embodiments, the first solution is an alcohol. In various embodiments, the first solution is ethanol. In various embodiments, the first solution is methanol.
[0099] In various embodiments, the payload encapsulated by the LNP is dissolved in the second solution. In various embodiments, the payload encapsulated by the LNP is dissolved in the first solution. In various embodiments, the payload is encapsulated by a third water-miscible solvent.
[0100] In various embodiments, at least two of the solutions are different phases. In various embodiments, three solutions are injected into each other. In various embodiments, at least four solutions are injected into each other. In various embodiments, there is at least one organic phase and at least one aqueous phase.
[0101] In various embodiments, one of the solutions contains an aqueous solvent. In various embodiments, the aqueous solvent is an aqueous buffer.
[0102] The injection of one solution into another is controlled by a robotic liquid handler. As used herein, the term “robotic liquid handler” means a device capable of automatically pipetting, transferring, and mixing liquids in parallel into multiple wells, microwells, or other liquid reservoirs. In various embodiments, a robotic liquid handler can deliver liquids of different compositions or in different quantities to different wells, microwells, or liquid reservoirs in parallel. In various embodiments, a robotic liquid handler can pipette, transfer, and mix liquids into different wells, microwells, or liquid reservoirs in parallel at different speeds or durations.
[0103] In various embodiments, after injecting one solution into the second solution, the robotic liquid handler repeatedly picks up and reinjects the solution, thereby mixing at least two solutions. In various embodiments, the rate and duration of this injection and / or mixing are varied to determine the optimal parameters for LNP formation. In various embodiments, the injection and / or mixing rate varies from 0.1 ml / s to 0.9 ml / s. In various embodiments, the initial injection rate (i.e., the first injection of liquid) is performed at a rate of 0.1 ml / s to 0.9 ml / s. See Figure 1. In various embodiments, the subsequent injection / mixing is performed over a period of 1 to 10 seconds (10 × mixing at 0.1 ml / s to 0.9 ml / s).
[0104] In various embodiments, LNP formation is completed in at least one microplate. In various embodiments, the microplate consists of multiple microwells, and the formation conditions (e.g., lipid species, lipid composition, total lipid concentration, payload, payload loading ratio, phase species) vary between microwells. The microplate can be of any size and may contain any number of microwells. In various embodiments, the microplate contains 4, 6, 8, 12, 24, 48, 96, 384, and 1536 microwells.
[0105] One advantage of the HTS method provided herein is that LNP formation can occur rapidly in small amounts of solution. The method disclosed herein reduces material consumption by a factor of 10 and improves processing output by a factor of 100 (see Figure 11). LNP formation in microwells uses considerably less material than LNPs formed using, for example, microfluidic-based preparations. In various embodiments, the microwells have volumes of approximately 10 μL, 20 μL, 30 μL, 40 μL, 50 μL, 60 μL, 70 μL, 80 μL, 90 μL, 100 μL, 125 μL, 150 μL, 175 μL, 200 μL, 250 μL, 350 μL, 360 μL, 400 μL, 500 μL, 1000 μL, 2000 μL, 3000 μL, and 4000 μL.
[0106] Lipid nanoparticles (LNPs) This specification provides optimized lipid nanoparticles and methods for optimizing the production of these lipid nanoparticles, "LNPs." As used herein, the terms "lipid nanoparticles" or "LNPs" refer to a composition comprising (i) a plurality of self-assembling molecules (the self-assembling molecules comprising lipid components) and (ii) a payload. LNPs optimized for production using the present invention can be used for any purpose. In various embodiments, optimized LNPs may be used to deliver vaccines. In various embodiments, optimized LNPs may be used to deliver drugs to patients in need. LNPs may carry any payload, including but not limited to nucleic acids, peptides, proteins, and small molecules. Furthermore, LNPs may consist solely of lipids (e.g., liposomes), or they may contain other components such as self-assembling polymers or proteins.
[0107] In various embodiments, the LNP is an optimized LNP manufactured using the above techniques. In various embodiments, the optimized LNP is manufactured by the following steps: (i) obtaining a first solution containing an aqueous phase; (ii) obtaining a second solution containing an organic phase and a plurality of molecules that can self-assemble, wherein the first and second solutions are miscible; (iii) dissolving at least one payload molecule in either the first or second solution; (iv) using a robotic liquid handler to prepare the phases having various compositions and dispense them into a plurality of wells; and (v) mixing the first and second solutions to obtain lipid nanoparticles in which the payload is encapsulated using the robotic handler under conditions suitable for LNP formation. The LNPs are produced by a method comprising: (vi) measuring at least one of the following conditions: type of self-assembling molecule, composition ratio of the self-assembling molecule, ratio and / or concentration of the self-assembling molecule to the payload, phase, buffer type and pH selection, injection sequence, injection rate, mixing rate, volume, phase ratio, injection duration, and mixing duration, which vary between different wells; (vi) measuring at least one of the following: encapsulation efficiency, particle size distribution, purification and particle recovery rate, and formulation stability of the LNPs; (vii) determining optimal parameters for producing the LNP preparation; and (viii) producing the LNP preparation based on the optimal parameters.
[0108] In various embodiments, the present invention relates to a method for producing LNPs using a high-throughput method, the method comprising the steps of: (i) obtaining a first solution comprising an aqueous phase; (ii) obtaining a second solution comprising an organic phase and a plurality of molecules capable of self-assembling, wherein the first solution and the second solution are miscible; (iii) dissolving at least one payload molecule in either the first solution or the second solution; (iv) preparing the phases having various compositions and dispensing them into a plurality of wells using a robotic liquid handler; and (v) mixing the first solution and the second solution to obtain lipid nanoparticles in which the payload is encapsulated using the robotic handler under conditions suitable for LNP formation.
[0109] self-assembling molecules As used herein, the term “self-assembling molecule” refers to any molecule capable of achieving a defined configuration without guidance or control from an external source. An optimized LNP may consist of a single type of self-assembling molecule or multiple types of self-assembling molecules. In various embodiments, an optimized LNP may include a lipid component having at least one lipid molecule. In various embodiments, an LNP may include polymer molecules and / or protein / peptide molecules. In various embodiments, the self-assembling molecules of an LNP may consist solely of lipid molecules.
[0110] The lipid component may consist of a single lipid species or two or more lipid species. In various embodiments of the present invention, the relative composition of lipids in the LNP preparation varies. In various embodiments, different lipid species or combinations of different lipid species are evaluated when considering the optimal parameters for the production of a given LNP formulation. In various embodiments, at least one lipid molecule is pegylated. In various embodiments, the lipid component may consist of phospholipids.
[0111] In various embodiments, the LNP formulation may comprise one or more cationic or ionizable lipids. In some embodiments, the cationic lipids may be cKK-E12, OF-02, C12-200, MC3, DLinDMA, DLinkC2DMA, ICE (imidazole-based), HGT5000, HGT5001, HGT4003, DODAC, DDAB, DMRIE, DOSPA, DOGS, DODAP, DODMA and DMDMA, DODAC, DLenDMA, DMRIE, ClinDMA, CpLinDMA, DMOBA, DOcarbDAP, DLinDAP, DLincarbDAP, DLinCDAP, KLin-K-DMA, DLin- The following are selected from the group consisting of K-XTC2-DMA, 3-(4-(bis(2-hydroxydodecyl)amino)butyl)-6-(4-((2-hydroxydodecyl)(2-hydroxyundecyl)amino)butyl)butyl)-1,4-dioxane-2,5-dione (target 23), 3-(5-(bis(2-hydroxydodecyl)amino)pentan-2-yl)-6-(5-((2-hydroxydodecyl)(2-hydroxyundecyl)amino)pentan-2-yl)-1,4-dioxane-2,5-dione (target 24), N1GL, N2GL, V1GL, and combinations thereof.
[0112] In some embodiments, one or more cationic or ionizable lipids are aminolipids. In various embodiments, the aminolipids are primary, secondary, tertiary, or quaternary amines, pyrrolidines, or piperidines. Aminolipids suitable for use in the present invention include those described in International Publication No. 2017180917, which is incorporated herein by reference. Exemplary aminolipids in International Publication No. 2017180917 are described in paragraph
[0113] These include, for example, DLin-MC3-DMA(MC3), (13Z,16Z)-N,N-dimethyl-3-nonyldocosa-13,16-diene-1-amine (L608), and compound 18. Other aminolipids include compound 2, compound 23, compound 27, compound 10, and compound 20. Further aminolipids suitable for use in the present invention include those described in International Publication No. 2017112865, which is incorporated herein by reference. Exemplary aminolipids in International Publication No. 2017112865 include compounds of formula (I), (Ial)-(Ia6), (lb), (II), (Ila), (III), (Ilia), (IV), (17-1), (19-1), (19-11), and (20-1), as well as the compounds in paragraphs
[0185] ,
[0201] , and
[0276] . In some embodiments, cationic lipids suitable for use in the present invention include those described in International Publication No. 2016118725, which is incorporated herein by reference. Exemplary cationic lipids in International Publication No. 2016118725 include KL22 and KL25, among others. In some embodiments, cationic lipids suitable for use in the present invention include those described in International Publication No. 2016118724, which is incorporated herein by reference. Examples of cationic lipids in International Publication No. 2016118725 include KL10, 1,2-dilinoleyloxy-N,N-dimethylaminopropane (DLin-DMA), and KL25.
[0114] In some embodiments, the LNP formulation comprises one or more noncationic lipids. In some embodiments, one or more noncationic lipids are selected from DSPC (1,2-distearoyl-sn-glycero-3-phosphocholine), DPPC (1,2-dipalmitoyl-sn-glycero-3-phosphocholine), DOPE (1,2-dioleyl-sn-glycero-3-phosphoethanolamine), DOPC (1,2-dioleyl-sn-glycero-3-phosphotidylcholine), DPPE (1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine), DMPE (1,2-dimyristoyl-sn-glycero-3-phosphoethanolamine), and DOPG (1,2-dioleoyl-sn-glycero-3-phospho(1'-rac-glycerol)).
[0115] In some embodiments, the LNP formulation comprises one or more PEG-modified lipids. In some embodiments, one or more PEG-modified lipids are C6-C 20 The PEG lipid contains a poly(ethylene) glycol chain up to 5 kDa in length covalently bonded to a lipid having a long alkyl chain. The PEG lipid can be selected from a non-limiting group consisting of PEG-modified phosphatidylethanolamine, PEG-modified phosphatidic acid, PEG-modified ceramide, PEG-modified dialkylamine, PEG-modified diacylglycerol, and nad PEG-modified dialkylglycerol. For example, the PEG lipid may be PEG-c-DOMG, PEG-DMG, PEG-DLPE, PEG-DMPE, PEG-DPPC, or PEG-DSPE lipid.
[0116] In various embodiments, the percentage of PEGylated lipids in LNPs (i.e., PEG density) varies. The polyethylene glycol (PEG) density in LNPs is known to affect particle size, surface charge, and stability. In various embodiments, the PEG density varies between approximately 0.1% and approximately 10%. In various embodiments, the PEG density varies between approximately 0.2% and approximately 9%. In various embodiments, the PEG density varies between approximately 0.3% and approximately 8%. In various embodiments, the PEG density varies between approximately 0.4% and approximately 7%. In various embodiments, the PEG density varies between approximately 0.5% and approximately 6%. In various embodiments, the PEG density varies between approximately 0.5% and approximately 5%.
[0117] In various embodiments, the total concentration of lipid components present in the solution for LNP preparation varies to achieve optimal properties of any given LNP. In various embodiments, the total lipid concentration varies between approximately 0.1 mM and approximately 8 mM. In various embodiments, the total lipid concentration varies between approximately 0.2 mM and approximately 7 mM. In various embodiments, the total lipid concentration varies between approximately 0.3 mM and approximately 6 mM. In various embodiments, the total lipid concentration varies between approximately 0.4 mM and approximately 4 mM. In various embodiments, the total lipid concentration varies between approximately 0.5 mM and approximately 3 mM.
[0118] In various embodiments, LNP contains two or more types of lipids. In various embodiments, LNP contains at least two types of lipids. In various embodiments, LNP contains at least three types of lipids. In various embodiments, LNP contains at least four types of lipids. In various embodiments, LNP contains at least five types of lipids. In various embodiments, LNP contains at least six types of lipids. In various embodiments, LNP contains at least seven types of lipids.
[0119] The lipid component of the nanoparticle composition may include one or more structural lipids. The nanoparticle composition of the present invention may include structural lipids (for example, cholesterol fecosterol, sitosterol, campesterol, stigmasterol, brassicasterol, ergosterol, tomatidine, tomatine, ursolic acid, or alpha-tocopherol).
[0120] The lipid component of the nanoparticle composition may include one or more phospholipids, for example, one or more (poly)unsaturated lipids. Generally, such lipids may include a phospholipid portion and one or more fatty acid portions.
[0121] The phospholipid portion may be selected from an unrestricted group consisting of phosphatidylcholine, phosphatidylethanolamine, phosphatidylglycerol, phosphatidylserine, phosphatidic acid, 2-lysophosphatidylcholine, and sphingomyelin. The fatty acid portion may be selected from an unrestricted group consisting of lauric acid, myristic acid, myristoleic acid, palmitic acid, palmitoleic acid, stearic acid, oleic acid, linoleic acid, α-linolenic acid, erucic acid, phytanic acid, arachidic acid, arachidonic acid, eicosapentaenoic acid, behenic acid, docosapentaenoic acid, and docosahexaenoic acid. Non-natural species, including natural species with modifications and substitutions including branching, oxidation, cyclization, and alkynes, are also considered.
[0122] In some embodiments, the nanoparticle composition may comprise 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), or both DSPC and DOPE. Phospholipids useful in the compositions and methods of the present invention include DSPC, DOPE, 1,2-dilinoleoyl-sn-glycero-3-phosphocholine (DLPC), 1,2-dimyristoyl-sn-glycero-phosphocholine (DMPC), 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), and 1,2-diundecanoyl-sn -Glycero-phosphocholine (DUPC), 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC), 1,2-di-O-octadecenyl-sn-glycero-3-phosphocholine (18:0 diether PC), 1-oleoyl-2-cholesterylhemisuccinoyl-sn-glycero-3-phosphocholine (OChemsPC), 1-hexadecyl-sn-glycero-3-phosphocholine (C16 Lyso PC), 1,2-dilinolenoyl-sn-glycero-3-phosphocholine, 1,2-diarachidonoyl-sn-glycero-3-phosphocholine, 1,2-didocosahexaenoyl-sn-glycero-3-phosphocholine, 1,2-difytanol-sn-glycero-3-phosphoethanolamine (ME 16.0 A non-limiting group consisting of PE, 1,2-distearoyl-sn-glycero-3-phosphoethanolamine, 1,2-dilinolenoyl-sn-glycero-3-phosphoethanolamine, 1,2-dilinolenoyl-sn-glycero-3-phosphoethanolamine, 1,2-diarachidonoyl-sn-glycero-3-phosphoethanolamine, 1,2-didocosahexaenoyl-sn-glycero-3-phosphoethanolamine, 1,2-dioleoyl-sn-glycero-3-phospho-rac-(1-glycerol) sodium salt (DOPG), and sphingomyelin may be selected.
[0123] The LNP composition may contain one or more components in addition to those described in the previous section. For example, the nanoparticle composition may contain one or more hydrophobic small molecules such as vitamins (e.g., vitamin A or vitamin E) or sterols.
[0124] The LNP composition may also contain one or more permeability-enhancing molecules, carbohydrates, polymers, therapeutic agents, surface modifiers, or other components. Permeability-enhancing molecules may, for example, be those described in U.S. Patent Application Publication No. 2005 / 0222064. Carbohydrates may include monosaccharides (e.g., glucose) and polysaccharides (e.g., glycogen and its derivatives and analogs).
[0125] The polymer may be included in the LNP composition and / or used to encapsulate or partially encapsulate the LNP composition. The polymer may be biodegradable and / or biocompatible. The polymer may be selected from, but is not limited to, polyamines, polyethers, polyamides, polyesters, polycarbamates, polyureas, polycarbonates, polystyrenes, polyimides, polysulfones, polyurethanes, polyacetylenes, polyethylenes, polyethyleneimines, polyisocyanates, polyacrylates, polymethacrylates, polyacrylonitriles, and polyarylates. For example, polymers include poly(caprolactone) (PCL), ethylene vinyl acetate polymer (EVA), poly(lactic acid) (PLA), poly(L-lactic acid) (PLLA), poly(glycolic acid) (PGA), poly(lactic acid-co-glycolic acid) (PLGA), poly(L-lactic acid-co-glycolic acid) (PLLGA), poly(D,L-lactide) (PDLA), poly(L-lactide) (PLLA), poly(D,L-lactide-co-caprolactone), poly(D,L-lactide-co-PEO-co-D,L-lactide), poly(D,L-lactide-co-D,Polyalkylenes such as L-lactide, polyalkylcyanoclarate, polyurethane, poly-L-lysine (PLL), hydroxypropyl methacrylate (HPMA), polyethylene glycol, poly-L-glutamic acid, poly(hydroxy acid), polyanhydride, polyoltoester, poly(esteramide), polyamide, poly(ester ether), polycarbonate, polyethylene, polypropylene, polyalkylene glycols such as poly(ethylene glycol) (EVA), polyalkylene oxide (PEO), poly(ethylene terephthalate), poly(ethylene terephthalate), polyvinyl alcohol (PVA), polyvinyl ether, polyvinyl esters such as poly(vinyl acetate), polyhalogenated vinyls such as poly(vinyl chloride) (PVC), polyvinylpyrrolidone, polysiloxane, polystyrene (PS), polyurethane, derivatized cellulose such as alkylcellulose, hydroxyalkylcellulose, cellulose ether, cellulose ester, Nitrocellulose, hydroxypropylcellulose, carboxymethylcellulose, acrylic acid polymers, such as poly(methyl(meth)acrylate) (PMMA), poly(ethyl(meth)acrylate), poly(butyl(meth)acrylate), poly(isobutyl(meth)acrylate), poly(hexyl(meth)acrylate), poly(isodecyl(meth)acrylate), poly(lauryl(meth)acrylate), poly(phenyl(meth)acrylate), poly(methyl acrylate) Examples include poly(isopropyl acrylate), poly(isobutyl acrylate), poly(octadecyl acrylate) and their copolymers and mixtures, polydioxanone and its copolymers, polyhydroxyalkanoates, polypropylene fumarate, polyoxymethylene, poloxamer, polyoxamine, poly(ortho)esters, poly(butyric acid), poly(valeric acid), poly(lactidoco-caprolactone) and trimethylene carbonate, and polyvinylpyrrolidone.
[0126] Therapeutic agents may include, but are not limited to, cytotoxic agents, chemotherapeutic agents, and other therapeutic agents. Examples of cytotoxic agents include taxol, cytochalasin B, gramicidin D, ethidium bromide, emetine, mitomycin, etoposide, teniposide, vincristine, vinblastine, colchicine, doxorubicin, daunorubicin, dihydroxyanthracine dione, mitoxantrone, mitramycin, actinomycin D, 1-dehydrotestosterone, glucocorticoids, procaine, tetracaine, lidocaine, propranolol, puromycin, meitansinoids, lachemycin, and their analogues. Radioactive ions can also be used as therapeutic agents and may include, for example, radioactive iodine, strontium, phosphorus, palladium, cesium, iridium, cobalt, yttrium, samarium, and praseodymium. Other therapeutic agents may include, for example, antimetabolites (e.g., methotrexate, 6-mercaptopurine, 6-thioguanine, cytarabine and 5-fluorouracil, and decarbazine), alkylating agents (e.g., mechloretamine, thiotepa, chlorambucil, lacemycin, melphalan, carmustine, lomustine, cyclophosphamide, busulfan, dibromomannitol, streptozotocin, mitomycin C, and cis-dichlorodiamine platinum(II) (DDP), and cisplatin), anthracyclines (e.g., daunorubicin and doxorubicin), antibiotics (e.g., dactinomycin, bleomycin, mitramycin and anthramycin), and antimitotic agents (e.g., vincristine, vinblastine, taxol and meitansinoids).
[0127] Surface modifiers may include, but are not limited to, anionic proteins (e.g., bovine serum albumin), surfactants (e.g., cationic surfactants such as dimethyldioctadecylammonium bromide), sugars or sugar derivatives (e.g., cyclodextrin), nucleic acids, polymers (e.g., heparin, polyethylene glycol, and poloxamer), mucolytic agents (e.g., acetylcysteine, mugwort, bromelain, papain, clerodendrum, bromhexine, carbocysteine, eprazinon, mesna, ambroxol, sobrelol, domidor, letostin, stepronin, thiopronin, gelzolin, thymosin 134, dorunase alpha, neltenexin, and erdosteine), and DNases (e.g., rhDNase). Surface modifiers may be placed within and / or on the surface of the LNP composition (e.g., by coating, adsorption, covalent bonding, or other processes).
[0128] In addition to these components, the LNP composition of the present invention may contain any substance useful in a pharmaceutical composition. For example, the LNP composition may contain one or more pharmaceutically acceptable excipients or auxiliary components, such as, but not limited to, one or more solvents, dispersion media, diluents, dispersion aids, suspension aids, granulation aids, disintegrants, fillers, flow accelerators, liquid vehicles, binders, surfactants, isotonic agents, thickeners or emulsifiers, buffers, lubricants, oils, preservatives, and other types. Excipients such as waxes, butters, colorants, coatings, flavorings, and fragrances may also be included. Pharmaceutically acceptable excipients are well known in the art (e.g., Remington's The Science and Practice of Pharmacy, 21st Edition, ARGennaro; Lippincott, Williams & Wilkins, Baltimore, Md., 2006).
[0129] Examples of diluents include, but are not limited to, calcium carbonate, sodium carbonate, calcium phosphate, dicalcium phosphate, calcium sulfate, calcium hydrogen phosphate, sodium lactose, sucrose, cellulose, microcrystalline cellulose, kaolin, mannitol, sorbitol, inositol, sodium chloride, dried starch, corn starch, powdered sugar, and / or combinations thereof. The granulating and dispersing agents may be selected from a non-limiting list consisting of potato starch, corn starch, tapioca starch, sodium starch glycolate, clay, alginic acid, guar gum, citrus pulp, agar, bentonite, cellulose and wood products, natural sponges, cation exchange resins, calcium carbonate, silicates, sodium carbonate, cross-linked poly(vinylpyrrolidone) (crospovidone), sodium carboxymethyl starch (sodium starch glycolate), carboxymethylcellulose, cross-linked sodium carboxymethylcellulose (croscarmellose), methylcellulose, pregelatinized starch (starch 1500), microcrystalline starch, water-insoluble starch, calcium carboxymethylcellulose, magnesium aluminum silicate (VEEGUM®), sodium lauryl sulfate, quaternary ammonium compounds, and / or combinations thereof.
[0130] The surfactants and / or emulsifiers include, but are not limited to, natural emulsifiers (e.g., acacia, agar, alginic acid, sodium alginate, tragacanth, cartilage, cholesterol, xanthan gum, pectin, gelatin, egg yolk, casein, wool fat, cholesterol, wax, and lecithin), colloidal clays (e.g., bentonite [aluminum silicate] and VEEGUM® [magnesium aluminum silicate]), long-chain amino acid derivatives, high molecular weight alcohols (e.g., stearyl alcohol, cetyl alcohol, oleyl alcohol, triacetin monostearate, ethylene glycol distearate, glyceryl monostearate, and propylene glycol monostearate, polyvinyl alcohol), carbomers (e.g., carboxypolymethylene, polyacrylic acid, acrylic acid polymers, and carboxyvinyl polymers), carrageenan, cellulose derivatives (e.g., sodium carboxymethylcellulose, powdered cellulose, hydroxymethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, methylcellulose), sorbitan fatty acid esters (e.g., poly Oxyethylene sorbitan monolaurate [TWEEN® 20], polyoxyethylene sorbitan [TWEEN® 60], polyoxyethylene sorbitan monooleate [TWEEN® 80], sorbitan monopalmitate [SPAN® 40], sorbitan monostearate [SPAN® 60], sorbitan tristearate [SPAN® 65], glyceryl monooleate, sorbitan monooleate [SPAN® 80]), polyoxyethylene esters (e.g., polyoxyethylene esters) Ethylene monostearate [MYRJ(registered trademark) 45], polyoxyethylene hydrogenated castor oil, polyethoxylated castor oil, polyoxymethylene stearate and SOLUTOL(registered trademark), sucrose fatty acid ester, polyethylene glycol fatty acid ester (e.g., CREMOPHOR(registered trademark)), polyoxyethylene ether (e.g., polyoxyethylene lauryl ether [BRIJ(registered trademark) 30]), poly(vinylpyrrolidone), diethylene glycol monolaurate, triethanolamine oleate, sodium oleate,Potassium oleate, ethyl oleate, oleic acid, ethyl laurate, sodium lauryl sulfate, PLURONIC® F 68, POLOXAMER® 188, cetrimonium bromide, cetylpyridinium chloride, benzalkonium chloride, sodium doxate, and / or combinations thereof may be used.
[0131] The binders may be starches (e.g., corn starch and starch paste); gelatin; sugars (e.g., sucrose, glucose, dextrose, dextrin, molasses, lactose, lactitol, mannitol); natural and synthetic rubbers (e.g., acacia, sodium alginate, Irish moss extract, panwal gum, ghati gum, Isapol husk mucus, carboxymethylcellulose, methylcellulose, ethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, microcrystalline cellulose, cellulose acetate, poly(vinylpyrrolidone), magnesium aluminum silicate (VEEGUM®), and oat gum arabic); alginates; polyethylene oxide; polyethylene glycol; inorganic calcium salts; silicic acid; polymethacrylate; waxes; water; alcohols; and combinations thereof, or any other suitable binders.
[0132] Examples of preservatives, but not limited to, include antioxidants, chelating agents, antimicrobial preservatives, antifungal preservatives, alcohol preservatives, acidic preservatives, and / or other preservatives. Examples of antioxidants, but not limited to, include alpha-tocopherol, ascorbic acid, acorbyl palmitate, butylated hydroxyanisole, butylated hydroxytoluene, monothioglycerol, potassium metabisulfite, propionic acid, propyl gallate, sodium ascorbate, sodium bisulfite, sodium metabisulfite, and / or sodium sulfite. Examples of chelating agents include ethylenediaminetetraacetic acid (EDTA), citric acid monohydrate, disodium edetate, dipotassium edetate, edetate, fumaric acid, malic acid, phosphoric acid, sodium edetate, tartaric acid, and / or trisodium edetate. Examples of antimicrobial preservatives include, but are not limited to, benzalkonium chloride, benzethonium chloride, benzyl alcohol, bronopol, cetrimide, cetylpyridinium chloride, chlorhexidine, chlorobutanol, chlorocresol, chloroxylenol, cresol, ethyl alcohol, glycerin, hexetidine, imidourea, phenol, phenoxyethanol, phenylethyl alcohol, phenylmercury nitrate, propylene glycol, and / or thimerosal. Examples of antifungal preservatives include, but are not limited to, butylparaben, methylparaben, ethylparaben, propylparaben, benzoic acid, hydroxybenzoic acid, potassium benzoate, potassium sorbate, sodium benzoate, sodium propionate, and / or sorbic acid. Examples of alcohol preservatives include, but are not limited to, ethanol, polyethylene glycol, phenol, benzyl alcohol, phenol compounds, bisphenol, chlorobutanol, hydroxybenzoate, and / or phenylethyl alcohol. Examples of acidic preservatives include, but are not limited to, vitamin A, vitamin C, vitamin E, beta-carotene, citric acid, acetic acid, dehydroascorbic acid, ascorbic acid, sorbic acid, and / or phytic acid.Other preservatives include, but are not limited to, tocopherol, tocopherol acetate, desulfoxime mesylate, cetrimide, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), ethylenediamine, sodium lauryl sulfate (SLS), sodium lauryl ether sulfate (SLES), sodium bisulfite, sodium metabisulfite, potassium sulfite, potassium metabisulfite, GLYDANT PLUS®, PHENONIP®, methylparaben, GERMALL® 115, GERMABEN® II, NEOLONE®, KATHON®, and / or EUXYL®.
[0133] Examples of buffers include citrate buffer, acetate buffer, phosphate buffer, ammonium chloride, calcium carbonate, calcium chloride, calcium citrate, calcium glubionate, calcium gluconate, calcium gluconate, d-gluconic acid, calcium glycerophosphate, calcium lactate, calcium lactobionate, propanoic acid, calcium levulinate, pentanoic acid, dibasic calcium phosphate, phosphoric acid, tribasic calcium phosphate, calcium hydroxide phosphate, potassium acetate, potassium chloride, potassium gluconate, potassium mixture, dibasic potassium phosphate, monobasic potassium phosphate, potassium phosphate mixture, sodium acetate, sodium bicarbonate, sodium chloride, sodium citrate, sodium lactate, dibasic sodium phosphate, monobasic sodium phosphate, sodium phosphate mixture, tromethamine, aminosulfonic acid buffer (e.g., HEPES), magnesium hydroxide, aluminum hydroxide, alginic acid, pyrogen-free water, isotonic saline, Ringer's solution, ethyl alcohol, and / or combinations thereof. The lubricant may be selected from a non-limiting group consisting of magnesium stearate, calcium stearate, stearic acid, silica, talc, malt, glyceryl behenate, hydrogenated vegetable oil, polyethylene glycol, sodium benzoate, sodium acetate, sodium chloride, leucine, magnesium lauryl sulfate, sodium lauryl sulfate, and combinations thereof.
[0134] Examples of oils include, but are not limited to, almonds, apricot kernels, avocados, babassu, bergamot, black cow's eye, borage, cade, chamomile, canola, caraway, carnauba, castor oil, cinnamon, cocoa butter, coconut, cod liver, coffee, corn, cottonseed, emu, eucalyptus, evening primrose, fish, flaxseed, geraniol, gourd, grape seeds, hazelnuts, hyssop, isopropyl myristate, jojoba, kuku peanuts, lavandin, lavender, lemon, lissic cubeba, macadamia nuts, mallow, mango seeds, meadowfoam seeds, mink, nutmeg, olive, orange, and orange. Examples include giraffe, palm, palm kernel, peach kernel, peanut, poppy seed, pumpkin seed, rapeseed, rice bran, rosemary, safflower, sandalwood, sascana, savory, sea buckthorn, sesame, shea butter, silicone, soybean, sunflower, tea tree, thistle, camellia, vetiver, walnut, and wheat germ oil, as well as butyl stearate, caprylic triglyceride, capric triglyceride, cyclomethicone, diethyl sebacate, dimethicone 360, simethicone, isopropyl myristate, mineral oil, octyldodecanol, oleyl alcohol, silicone oil, and / or combinations thereof.
[0135] In various embodiments, LNPs may be liposomes. In various embodiments, LNPs may be polymer-lipid nanoparticles. In various embodiments, LNPs may contain additional protein or peptide molecules.
[0136] payload The LNPs of the present invention are manufactured for encapsulating payloads. The term "payload" refers to any chemical entity, pharmaceutical, drug (such drug may be, but is not limited to, small molecules, inorganic solids, polymers, or biopolymers), small molecule, nucleic acid (e.g., DNA, RNA, siRNA, etc.), protein, peptide, etc., that forms a complex with the lipid nanoparticle formulations described herein. The payload also includes, but is not limited to, a candidate (e.g., an unknown structure and / or function) for treating or preventing a disease, illness, disorder, or impairment of bodily function, and includes a test compound which is both a known therapeutic compound and a potential therapeutic compound. The test compound may be determined to be therapeutic by screening using the screening method of this disclosure.
[0137] In various embodiments, the payload consists of one or more nucleotides. For example, in various embodiments, the payload is an oligonucleotide. In various embodiments, such payload-encapsulating LNPs may be characterized by an N:P ratio. As used herein, “N / P ratio” refers to the ratio of positively charged polymer amine (N = nitrogen) groups to negatively charged nucleic acid phosphate (P) groups. The N / P ratio plays an important role in intracellular payload delivery. In various embodiments, the N:P ratio of the payload varies. In various embodiments, the N:P ratio varies between about 0.5 and about 5. In various embodiments, the N:P ratio varies between about 0.25 and about 10. In various embodiments, the N:P ratio is about 0.1, about 0.2, about 0.25, about 0.5, about 1, about 1.5, about 2, about 2.5, about 3, about 3.5, about 4, about 4.5, about 5, about 6, about 7, about 8, about 9, or about 10.
[0138] In various embodiments, the payload is an oligonucleotide. In various embodiments, the oligonucleotide is an antisense molecule. In various embodiments, the oligonucleotide is a siRNA. In various embodiments, the oligonucleotide is an shRNA. The oligonucleotide can be of various lengths. In various embodiments, the oligonucleotide is about 1, about 2, about 3, about 4, about 5, about 6, about 7, about 8, about 9, about 10, about 11, about 12, about 13, about 14, about 15, about 16, about 17, about 18, about 19, about 20, about 21, about 22, about 23, about 24, about 25, about 26, about 27, about 28, about 29, about 30, about 31, about 32, about 33, about 34, about 35, about 36, about 37, about 38, about 39, or about 40 nucleotides long. In various embodiments, the oligonucleotide is about 2 to about 40 nucleotides long. In various embodiments, the oligonucleotide is about 4 to about 35 nucleotides long. In various embodiments, the oligonucleotides are about 10 to about 30 nucleotides long. In various embodiments, the oligonucleotides are about 12 to about 17 nucleotides long.
[0139] In various embodiments, the payload is mRNA. In various embodiments, the mRNA is approximately 500 to 3000 nucleotides long. In various embodiments, the mRNA is 500, 1000, 1500, 2000, 2500, or 3000 nucleotides long. In various embodiments, the mRNA encodes an antigen peptide. In various embodiments, the mRNA is part of a vaccine.
[0140] In various embodiments, the payload is a polypeptide. In various embodiments, the polypeptide is approximately 1,000 to 10,000 Da. In various embodiments, the polypeptide is approximately 500 Da, 600 Da, 700 Da, 800 Da, 900 Da, 1,000 Da, 1,500 Da, 2,000 Da, 2,500 Da, 3,000 Da, 3,500 Da, 4,000 Da, 4,500 Da, 5,000 Da, 5,500 Da, 6,000 Da, 6,500 Da, 7,000 Da, 7,500 Da, 8,000 Da, 8,500 Da, 9,000 Da, 9,500 Da, 10,000 Da, 15,000 Da, or 20,000 Da.
[0141] In various embodiments, the payload is a small molecule. In various embodiments, the small molecule is about 100 Da to 1000 Da. In various embodiments, the small molecule is about 50 Da, about 60 Da, about 70 Da, about 80 Da, about 90 Da, about 100 Da, about 150 Da, about 200 Da, about 250 Da, about 300 Da, about 350 Da, about 400 Da, about 450 Da, about 500 Da, about 550 Da, about 600 Da, about 650 Da, about 700 Da, about 750 Da, about 800 Da, about 850 Da, about 900 Da, about 950 Da, about 1,000 Da, about 1,500 Da, or about 2,000 Da.
[0142] Pharmaceutical preparations In various embodiments, optimized lipid nanoparticles can be formulated whole or partially as a pharmaceutical formulation. The pharmaceutical formulation of the present invention may comprise one or more nanoparticle compositions. For example, a pharmaceutical composition may comprise one or more nanoparticle compositions comprising one or more different payloads. The pharmaceutical composition of the present invention may further comprise one or more pharmaceutically acceptable excipients or auxiliary components, such as those described herein. General guidelines for the formulation and manufacture of pharmaceutical compositions and drugs are available, for example, in Remington's The Science and Practice of Pharmacy, 21st Edition, ARGennaro; Lippincott, Williams & Wilkins, Baltimore, Md., 2006. Conventional excipients and auxiliary components may be used in any pharmaceutical composition of the present invention, except insofar as any conventional excipient or auxiliary component may be incompatible with one or more components of the nanoparticle compositions of the present invention. An excipient or auxiliary component may be incompatible with the components of a nanoparticle composition if its combination with the components may result in any undesirable biological or other adverse effect.
[0143] In some embodiments, one or more excipients or auxiliary components may constitute more than 50% of the total mass or volume of the pharmaceutical composition comprising the nanoparticle composition of the present invention. For example, one or more excipients or auxiliary components may constitute 50%, 60%, 70%, 80%, 90%, or more of pharmaceutically acceptable excipients. In some embodiments, pharmaceutically acceptable excipients are at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% pure. In some embodiments, the excipients are approved for use in humans and veterinary use. In some embodiments, the excipients are approved by the U.S. Food and Drug Administration. In some embodiments, the excipients are pharmaceutical grade. In some embodiments, the excipients meet the standards of the United States Pharmacopeia (USP), European Pharmacopoeia (EP), British Pharmacopoeia and / or International Pharmacopoeia.
[0144] The relative amounts of one or more nanoparticle compositions, one or more pharmaceutically acceptable excipients, and / or any additional components in the pharmaceutical compositions according to this disclosure will vary depending on the identity, size, and / or symptoms of the subject being treated, and further depending on the route through which the composition is administered. For example, a pharmaceutical composition may contain one or more nanoparticle compositions in amounts ranging from 0.1% to 100% (wt / wt).
[0145] Nanoparticle compositions and / or pharmaceutical compositions comprising one or more nanoparticle compositions can be administered to any patient or subject, including patients or subjects who can benefit from the therapeutic effect provided by delivering mRNA to one or more specific cells, tissues, organs, or systems or groups thereof, such as the renal system. The descriptions of nanoparticle compositions and pharmaceutical compositions comprising nanoparticle compositions provided herein relate primarily to compositions suitable for administration to humans, but it will be understood by those skilled in the art that such compositions are generally suitable for administration to any other mammals. Modifications of compositions suitable for administration to humans to make the compositions suitable for administration to various animals are well understood, and veterinary pharmacologists skilled in the art can design and / or carry out such modifications, if any, in ordinary experiments. Subjects to which the administration of the compositions is intended include, but are not limited to, humans, other primates, and other mammals, including commercially relevant mammals such as cattle, pigs, horses, sheep, cats, dogs, mice and / or rats.
[0146] Pharmaceutical compositions comprising one or more nanoparticle compositions can be prepared by any method known or to be developed in the field of pharmacology. Generally, such preparation methods involve associating the active ingredient with excipients and / or one or more other auxiliary components, and then, if desired or as needed, dividing, shaping and / or packaging the product into desired single or multi-dose units.
[0147] The pharmaceutical compositions described herein may be prepared, packaged, and / or sold in bulk as single unit doses and / or as multiple single unit doses. As used herein, “unit dose” is a discrete amount of a pharmaceutical composition (e.g., a nanoparticle composition) containing a predetermined amount of the active ingredient. The amount of the active ingredient is generally equal to the dose of the active ingredient that would be administered to a subject and / or a favorable proportion of such a dose, for example, half or one-third of such a dose.
[0148] The pharmaceutical compositions of the present invention can be prepared in various forms suitable for various routes and methods of administration. For example, the pharmaceutical compositions of the present invention can be prepared in liquid dosage forms (e.g., emulsions, microemulsions, nanoemulsions, solutions, suspensions, syrups, and elixirs), injectable dosage forms, solid dosage forms (e.g., capsules, tablets, pills, powders, and granules), topical and / or transdermal dosage forms (e.g., ointments, pastes, creams, lotions, gels, powders, solutions, sprays, inhalants, and patches), suspensions, powders, and other forms.
[0149] Liquid dosage forms for oral and parenteral administration include, but are not limited to, pharmaceutically acceptable emulsions, microemulsions, nanoemulsions, solutions, suspensions, syrups, and / or elixirs. In addition to the active ingredient, the liquid dosage form may contain, for example, water, or other solvents such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethylformamide, oils (especially cottonseed oil, peanut oil, corn oil, germ oil, olive oil, castor oil, and sesame oil), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycol, and fatty acid esters of sorbitan, as well as solubilizers, emulsifiers, and mixtures thereof, which are commonly used in the art. In addition to the inert diluent, the oral composition may contain adjuvants such as wetting agents, emulsifiers, and suspending agents, sweeteners, flavoring agents, and / or fragrances. In certain embodiments for parenteral administration, the composition is mixed with a solubilizer such as Cremophor®, alcohol, oil, modified oil, glycol, polysorbate, cyclodextrin, polymer, and / or combination thereof.
[0150] Injectable formulations, such as sterile aqueous or oily suspensions for injection, can be formulated according to known techniques using appropriate dispersants, wetting agents, and / or suspending agents. Sterile injectable formulations may be sterile injectable solutions, suspensions, and / or emulsions in non-toxic, parenterally acceptable diluents and / or solvents, for example, solutions in 1,3-butanediol. Acceptable excipients and solvents that can be used include water, Ringer's solution, USP, and isotonic sodium chloride solutions. Sterile non-volatile oils are conventionally used as solvents or suspensions. For this purpose, any non-irritating non-volatile oil containing synthetic monoglycerides or synthetic diglycerides may be used. Fatty acids, such as oleic acid, can be used in the preparation of injectables.
[0151] Injectable formulations can be sterilized, for example, by filtration through a bacterial-retaining filter and / or by incorporating a sterilizing agent in the form of a sterile solid composition that can be dissolved or dispersed in sterile water or other sterile injectable medium before use.
[0152] To extend the effect of the active ingredient, it is often desirable to delay its absorption from subcutaneous or intramuscular injection. This can be achieved by using a liquid suspension of a crystalline or amorphous material with low water solubility. The absorption rate of the drug then depends on the dissolution rate of the drug, which in turn may depend on the size and morphology of the crystals. Alternatively, delayed absorption of parenterally administered drug forms is achieved by dissolving or suspending the drug in an oil vehicle. Depot formulations for injection are produced by forming a microencapsulation matrix of the drug in a biodegradable polymer such as polylactide-polyglycolide. Depending on the ratio of drug to polymer and the properties of the specific polymer used, the drug release rate can be controlled. Other examples of biodegradable polymers include poly(orthoester) and poly(anhydrous). Depot injection formulations are prepared by encapsulating the drug in liposomes or microemulsions compatible with body tissues.
[0153] Compositions for rectal or vaginal administration are typically suppositories that can be prepared by mixing the composition with a suitable non-irritating excipient or carrier, such as cocoa butter, polyethylene glycol, or suppository wax, which is solid at ambient temperature but liquid at body temperature, and therefore melts in the rectum or vaginal cavity and releases the active ingredient.
[0154] Examples of solid dosage forms for oral administration include capsules, tablets, pills, films, powders, and granules. In such solid dosage forms, the active ingredient is mixed with at least one inert, pharmaceutically acceptable excipient, e.g., sodium citrate or dicalcium phosphate and / or fillers or bulking agents (e.g., starch, lactose, sucrose, glucose, mannitol, and silicic acid), binders (e.g., carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidinone, sucrose, and acacia), wetting agents (e.g., glycerol), disintegrants (e.g., agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate), solution retarders (e.g., paraffin), absorption enhancers (e.g., quaternary ammonium compounds), wetting agents (e.g., cetyl alcohol and glycerol monostearate), absorbents (e.g., kaolin and bentonite clay, silicates), and lubricants (e.g., talc, calcium stearate, magnesium stearate, solid polyethylene glycol, sodium lauryl sulfate), as well as mixtures thereof. In the case of capsules, tablets, and pills, the dosage form may include a buffering agent.
[0155] By using such excipients as lactose (i.e., milk sugar) and also as high molecular weight polyethylene glycol, similar types of solid compositions can be used as fillers for soft and hard gelatin capsules. Solid dosage forms such as tablets, sugar-coated tablets, capsules, pills, and granules can be prepared by coatings and shells, such as enteric coatings and other coatings known in the pharmaceutical art. They may optionally contain opacifiers, and these can be compositions that selectively delay the release of one or more active ingredients to specific parts of the intestinal tract, either preferentially or otherwise. Examples of usable embedding compositions include polymeric substances and waxes. By using such excipients as lactose (i.e., milk sugar) and also as high molecular weight polyethylene glycol, similar types of solid compositions can be used as fillers for soft and hard gelatin capsules.
[0156] Dosage forms for topical and / or transdermal administration of the composition may include ointments, pastes, creams, lotions, gels, powders, solutions, sprays, inhalants, and / or patches. Generally, the active ingredient is mixed with pharmaceutically acceptable excipients and / or any necessary preservatives and / or buffers as needed, under sterile conditions. Furthermore, this disclosure intends to use transdermal patches, which often have the additional advantage of providing controlled delivery of the compound to the body. Such dosage forms may be prepared, for example, by dissolving and / or dispensing the compound in a suitable medium. Alternatively or additionally, the rate can be controlled by providing a rate-controlled membrane and / or by dispersing the compound in a polymer matrix and / or gel.
[0157] Suitable devices for use in delivering the intradermal pharmaceutical compositions described herein include short-needle devices, such as those described in U.S. Patent Nos. 4,886,499; 5,190,521; 5,328,483; 5,527,288; 4,270,537; 5,015,235; 5,141,496; and 5,417,662. The intradermal compositions may be administered by devices that limit the effective penetration length of the needle into the skin, such as those described in International Publication No. 99 / 34850 and their functional equivalents. Suitable jet injectors are used to deliver the liquid composition to the dermis via a liquid jet syringe and / or via a needle that punctures the stratum corneum and generates a jet that reaches the dermis. Jet propulsion systems include, for example, U.S. Patent Nos. 5,480,381; 5,599,302; 5,334,144; 5,993,412; 5,649,912; 5,569,189; 5,704,911; 5,383,851; 5,893,397; 5,466,220; and 5 It is described in U.S. Patent Nos. 339,163; U.S. Patent Nos. 5,312,335; U.S. Patent Nos. 5,503,627; U.S. Patent Nos. 5,064,413; U.S. Patent Nos. 5,520,639; U.S. Patent Nos. 4,596,556; U.S. Patent Nos. 4,790,824; U.S. Patent Nos. 4,941,880; U.S. Patent Nos. 4,940,460; and International Publication Nos. 97 / 37705 and International Publication Nos. 97 / 13537. Ballistic powder / particle delivery devices that use compressed gas to accelerate the powder form of the vaccine through the outer layer of the skin to the dermis are suitable. Alternatively or additionally, conventional syringes may be used in the classic Mantot method for intradermal administration.
[0158] Formulations suitable for topical administration include, but are not limited to, liquid and / or semi-liquid formulations, such as liniments, lotions, oil-in-water and / or water-in-oil emulsions, such as creams, ointments and / or pastes, and / or solutions and / or suspensions. A formulation suitable for topical administration may contain, for example, about 1% to about 10% (wt / wt) of the active ingredient, although the concentration of the active ingredient may be as high as the solubility limit of the active ingredient in the solvent. Formulations for topical administration may further contain one or more additional ingredients described herein.
[0159] Pharmaceutical compositions may be prepared, packaged, and / or sold in formulations suitable for oral pulmonary administration. Such formulations may contain an active ingredient and include dry particles having a diameter in the range of about 0.5 nm to about 7 nm or about 1 nm to about 6 nm. Such compositions are conveniently in the form of a dry powder for administration using a device including a dry powder reservoir through which a flow of propellant can be directed to disperse the powder, and / or using a self-propelled solvent / powder dispenser such as a device including an active ingredient dissolved and / or suspended in a low-boiling point propellant in a sealed container. Such powders may include particles in which at least 98% (by weight) have a diameter greater than 0.5 nm and at least 95% (by number) have a diameter less than 7 nm. Alternatively, at least 95% (by weight) have a diameter greater than 1 nm and at least 90% (by number) have a diameter less than 6 nm. The dry powder composition may include a solid fine powder diluent such as sugar and is conveniently provided in unit dose form.
[0160] Low-boiling-point propellants generally include liquid propellants having a boiling point of less than 65°F at atmospheric pressure. Generally, the propellant may constitute 50% to 99.9% (wt / wt) of the composition, and the active ingredient may constitute 0.1% to 20% (wt / wt) of the composition. The propellant may further include additional components such as liquid nonionic and / or solid anionic surfactants and / or solid diluents (which may have a particle size similar to that of the particles containing the active ingredient).
[0161] Pharmaceutical compositions formulated for pulmonary delivery may provide the active ingredient in the form of droplets of solution and / or suspension. Such formulations may be prepared, packaged and / or sold as aqueous and / or diluted alcoholic solutions and / or suspensions (optionally sterile) containing the active ingredient and may be conveniently administered using any spraying and / or atomizing equipment. Such formulations may further contain one or more additional components, including but not limited to flavoring agents such as sodium saccharin, volatile oils, buffers, surfactants, and / or preservatives such as methyl hydroxybenzoate. The droplets delivered by this administration route may have an average diameter ranging from about 1 nm to about 200 nm.
[0162] Formulations described herein as useful for pulmonary delivery are useful for intranasal delivery of pharmaceutical compositions. Another formulation suitable for intranasal administration is a coarse powder containing the active ingredient and having average particles of about 0.2 μm to 500 μm. Such formulations are administered by snuff administration, i.e., by rapid inhalation through the nasal passages from a container of powder held near the nose.
[0163] Formulations suitable for intranasal administration may contain, for example, small amounts ranging from about 0.1% (wt / wt) to 100% (wt / wt) of the active ingredient and may contain one or more additional ingredients described herein. Pharmaceutical compositions may be prepared, packaged and / or sold in formulations suitable for buccal administration. Such formulations may be, for example, in the form of tablets and / or lozenges manufactured using conventional methods, and may contain, for example, 0.1% to 20% (wt / wt) of the active ingredient, with the remainder being an orally soluble and / or degradable composition, and optionally one or more additional ingredients described herein. Alternatively, formulations suitable for oral administration may include powders and / or aerosolized and / or sprayed solutions and / or suspensions containing the active ingredient. Such powdered, aerosolized, and / or aerosolized formulations, when dispersed, may have an average particle and / or droplet size ranging from about 0.1 nm to about 200 nm, and may further contain one or more of the additional ingredients described herein.
[0164] Pharmaceutical compositions may be prepared, packaged, and / or sold in formulations suitable for ophthalmic administration. Such formulations may, for example, be in the form of eye drops comprising a 0.1 / 1.0% (wt / wt) solution and / or suspension of the active ingredient in an aqueous or oily liquid excipient. Such drops may further comprise one or more of buffers, salts, and / or any additional ingredients described herein. Other useful ophthalmally administered formulations include those containing the active ingredient in microcrystalline form and / or liposomal preparations. Ear drops and / or eye drops are considered to be within the scope of this disclosure.
[0165] A nanoparticle composition comprising one or more payloads may be administered by any route. In some embodiments, compositions of the present invention comprising a preventive composition, a diagnostic composition, or an imaging composition comprising one or more nanoparticle compositions of the present invention may be administered by one or more of various routes including oral, intravenous, intramuscular, intra-arterial, intramedullary, intrathecal, subcutaneous, intraventricular, percutaneous or intradermal, interdermal, rectal, vaginal, intraperitoneal, topical (e.g., powder, ointment, cream, gel, lotion and / or drops), mucous membrane, nasal, buccal, enteral, intravitreous, intratumoral, sublingual, intranasal; by endotracheal infusion, bronchial infusion, and / or inhalation; as an oral spray and / or powder, a nasal spray and / or aerosol, and / or via a portal vein catheter. In some embodiments, the composition may be administered intravenously, intramuscular, intradermally, or subcutaneously. However, this disclosure encompasses the delivery of compositions of the present invention by any suitable route, taking into account possible advances in the science of drug delivery. Generally, the most appropriate route of administration depends on various factors, including the properties of the nanoparticle composition containing one or more mRNAs (e.g., its stability in various bodily environments such as blood flow and the gastrointestinal tract) and the patient's condition (e.g., whether the patient can tolerate a particular route of administration).
[0166] In certain embodiments, the compositions according to this disclosure, in a given dose, are approximately 0.0001 mg / kg to approximately 10 mg / kg, approximately 0.001 mg / kg to approximately 10 mg / kg, approximately 0.005 mg / kg to approximately 10 mg / kg, approximately 0.01 mg / kg to approximately 10 mg / kg, approximately 0.1 mg / kg to approximately 10 mg / kg, approximately 1 mg / kg to approximately 10 mg / kg, approximately 2 mg / kg to approximately 10 mg / kg, approximately 5 mg / kg to approximately 10 mg / kg, approximately 0.0001 mg / kg to approximately 5 mg / kg, approximately 0.001 mg / kg to approximately 5 mg / kg, and approximately 0.005 mg The doses may be administered at levels sufficient to deliver approximately 5 mg / kg, approximately 0.01 mg / kg to approximately 5 mg / kg, approximately 0.1 mg / kg to approximately 10 mg / kg, approximately 1 mg / kg to approximately 5 mg / kg, approximately 2 mg / kg to approximately 5 mg / kg, approximately 0.0001 mg / kg to approximately 1 mg / kg, approximately 0.001 mg / kg to approximately 1 mg / kg, approximately 0.005 mg / kg to approximately 1 mg / kg, approximately 0.01 mg / kg to approximately 1 mg / kg, or approximately 0.1 mg / kg to approximately 1 mg / kg, where a dose of 1 mg / kg provides 1 mg of the composition per kg of body weight of the subject. In certain embodiments, doses of the nanoparticle composition of the present invention can be administered at doses of approximately 0.005 mg / kg to approximately 5 mg / kg. The doses may be administered once or multiple times daily in the same or different amounts to obtain the desired level of mRNA expression and / or therapeutic, diagnostic, prophylactic, or imaging effect. The desired dose may be delivered, for example, three times a day, twice a day, once a day, every other day, every three days, weekly, every two weeks, every three weeks, or every four weeks. In certain embodiments, the desired dose may be delivered using multiple doses (e.g., two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, or more doses). In some embodiments, a single dose may be administered, for example, before or after a surgical procedure, or in the case of an acute disease, disorder, or symptom.
[0167] Nanoparticle compositions comprising one or more payloads may be used in combination with one or more other therapeutic, prophylactic, diagnostic, or imaging agents. “In combination” does not mean that the agents must be administered simultaneously and / or formulated for joint delivery, but these delivery methods are within the scope of this disclosure. For example, one or more nanoparticle compositions comprising one or more different mRNAs may be administered in combination. The compositions may be administered simultaneously with, before, or after one or more other desired therapeutic or medical treatments. Generally, each agent is administered in a dose and / or time schedule determined for that agent. In some embodiments, this disclosure encompasses the delivery of the compositions of the present invention or its imaging, diagnostic, or prophylactic compositions in combination with agents that improve bioavailability, reduce and / or modify metabolism, inhibit excretion, and / or alter distribution in the body.
[0168] It will be further understood that therapeutic, prophylactic, diagnostic, or imaging activators used in combination may be administered together in a single composition or separately in different compositions. Generally, it is expected that the combined agents will be used at levels not exceeding those used individually. In some embodiments, the combined level may be lower than that used individually.
[0169] The specific combination of treatments (therapeutic drugs or procedures) used in a combination regimen should take into account the suitability of the desired therapeutic drugs and / or procedures and the desired therapeutic effect to be achieved. It should also be understood that the treatments used may achieve the desired effect against the same disorder (for example, a composition useful for treating cancer may be administered concurrently with a chemotherapeutic agent) or achieve a different effect (for example, control of any adverse effects). [Examples]
[0170] Examples The following examples are presented not as limiting but to provide further information and support for the present invention. These examples demonstrate that an HTS method for optimizing LNP formation for optimal payload load and particle size distribution can be directly translated into scaled-up manufacturing methods such as microfluidic-based approaches. This HTS approach reduced material consumption by approximately 10-fold and improved processing output by approximately 100-fold. These results demonstrate the robustness and utility of the HTS method for optimizing LNP production and thus facilitate their clinical transition.
[0171] Materials and methods material 1,2-Distearoyl-sn-glycero-3-phosphocholine (DSPC), 1,2-Distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000](DSPE-PEG) 2000 Lipids containing ), and cationic 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP) were purchased from Avanti Polar Lipids (AL, USA). Ionizable lipid dilinoleylmethyl-4-dimethylaminobutyric acid (DLin-MC3-DMA, MC3) was obtained from MCE (NJ, USA), and cholesterol from Sigma (MO, USA). Two model ASOs, ASO-1 (13-mer, Na salt form) and ASO-2 (16-mer, Na salt form), were synthesized in-house. All other reagents were at least reagent grade and did not contain DNase / RNAse.
[0172] High-throughput preparation of ASO-loaded LNPs LNP formulations were screened for various lipid compositions, total lipid concentrations, and ASO loadings designed in 96-well plate matrices using LEA Library Studio software (Unchained Labs, CA, USA). For typical screening of ASO-1 loaded MC3 LNPs, ASO was dissolved in citrate buffer (25 mM, pH 4) at concentrations corresponding to N / P ratios of 5, 2, 1, and 0.5, and dispensed at 150 μl / well into 96-well plates (Greiner Bio One 655101, NC, USA) using a robotic liquid handler (TECAN® Freedom EVO, NC, USA). Various total lipid concentrations (0.2 or 0.4 μmol / well) and DSPE-PEG were also screened. 2000 Lipid mixtures having content (0, 1.5, 3, or 5 mol%) of total lipids were prepared by mixing individual lipid stocks (20 mg / ml in ethanol) and diluting with ethanol using a TECAN® robot. 50 μl of lipid was then rapidly dispensed into ASO plates at 0.5 ml / s, followed by phase mixing using a TECAN® robot in 10 pipetting steps (100 μl each) to promote self-assembly of ASO-loaded LNPs. The resulting plates contained 96 LNP samples (200 μl / well) varied under 32 parallel conditions (4 levels of ASO loading, 2 levels of total lipid concentration, and 4 levels of lipid composition; n=3). In other experiments, ionizable lipid MC3 was replaced with the permanently cationic lipid DOTAP, or 13-mer ASO-1 was replaced with 16-mer ASO-2, and similar formulation parameters were screened. The reverse dispensing sequence (injection of ASO solution into the lipid mixture), as well as different mixing rates and frequencies, were also investigated to optimize the phase mixing process.
[0173] Characterization of ASO-loaded LNP The structure of ASO-loaded LNPs was determined by cryo-transmission electron microscopy (cyro-TEM). Particle size distribution was measured using DLS. Briefly, ASO-loaded LNPs were 40-fold diluted in phosphate-buffered saline (PBS, pH 7.4) in a 96-well glass-bottom microplate (Greiner Bio One 655892, NC, USA) using a TECAN® robot, and the average particle size and particle size distribution (expressed as polydispersity %, PD%) were analyzed using a DynaPro® plate reader III (Wyatt Technology, CA, USA). 60 μl aliquots were adjusted to neutral pH by adding 15 μl of 0.5 M phosphate buffer (pH 7.4), then transferred to a filter plate (MWCO 100kD; AcroPrep, PALL, NY, USA), centrifuged (2,000xg, 10 min), and filtered. Next, the unsealed ASO in 50 μl of filtrate was analyzed using a UV plate reader (TECAN® Spark, NC, USA) for OD (Optical Dissolution). 260 The quantification was performed and the encapsulation efficiency percentage (%EE) of ASO was calculated: TIFF2023552815000001.tif14170
[0174] ASO standards were prepared in the same buffer and subjected to the same filtration process as the LNP samples. For stability experiments, 60 μl of LNP prepared under an N / P ratio of 1 was directly diluted 10-fold with PBS and stored at 4 or 40°C, and analyzed for particle size and ASO release over two weeks.
[0175] Microfluidic preparation of ASO-loaded LNPs A microfluidic approach was used for the scale-up preparation of ASO-loaded LNPs screened by the high-throughput approach described above. Briefly, this involved various concentrations of ASO-1 (dissolved in citrate buffer), total lipid concentration, and DSPE-PEG. 2000Lipids with varying content (dissolved in ethanol) were mixed using a microfluidic apparatus (NanoAssemblr®, Precision NanoSystems, BC, Canada) at an aqueous buffer / ethanol phase ratio of 3 / 1 and a constant total flow rate of 12 ml / min. The collected LNPs were purified by centrifugation-based ultrafiltration (MWCO 10kD; Amicon, MilliporeSigma, MA, USA) to remove free ASO and lipids, followed by buffer exchange with PBS. The particle size distribution of the LNPs was analyzed by DLS and ASO encapsulation using hydrophilic interaction liquid chromatography (HILIC). Briefly, encapsulated ASO was extracted from the purified LNPs by dissolving them in 0.75% Triton solution. A HILIC column (Waters ACQUITY UPLC BEH Amide, 130 Å, 1.7 μm, 3 mm x 50 mm), mobile phase A (80 / 20 (v / v) acetonitrile / 25 mM ammonium acetate in water), and mobile phase B (40 / 60 (v / v) acetonitrile / 25 mM ammonium acetate in water) were used for gradient elution of phase B from 0 to 100% within 10 minutes at a flow rate of 0.8 ml / min, a column temperature of 40°C, and a detection wavelength of 260 nm.
[0176] statistical analysis All results are presented as mean ± SD (n=3). Data were analyzed using one-way or two-way ANOVA followed by Turkey, Sidak, or Dunnett post-hoc tests using Prism 8.0 (GraphPad Software) to compare multiple groups. P-values less than 0.05 were considered statistically significant.
[0177] Example 1 Optimization of phase mixing processes using robotic liquid handlers To develop a high-throughput solvent injection method for LNP preparation, the effects of phase mixing on particle size and ASO encapsulation were first investigated. ASO-1 was encapsulated with 0.4 μmol of total lipids and 1.5 mol% DSPE-PEG. 2000LNPs composed of were loaded by charge-mediated complexing under an N / P ratio of 1. The lipid-containing ethanol phase was dispensed and mixed with the aqueous ASO phase using a TECAN® liquid handler at different pipetting speeds ranging from a minimum of 0.1 ml / s to a maximum of 0.9 ml / s, according to the instrument settings, and vice versa. Ethanol-buffer injection, under low, medium, or high speeds for injection and subsequent 10 mixings, produced similar LNPs with an average diameter of approximately 145 nm (Figure 1A), a %PD of approximately 18% (Figure 1B), and a %EE of approximately 83% of the ASO (Figure 1C). In contrast, buffer-ethanol injection at a low speed (0.1 ml / s) produced larger (average diameter approximately 220 nm) and more polydisperse (%PD approximately 41%) particles with a lower %EE (approximately 43%) (Figures 1A-1C). However, increasing the injection rate produced LNPs similar to those produced by ethanol-buffer injection, suggesting that rapid dissipation of concentrated lipids in the aqueous buffer is necessary for the formation of ASO-loaded LNPs. Next, LNPs were prepared under ethanol-buffer injection and subsequently phase-mixed at different pipetting counts and rates. A medium rate (0.5 ml / s) and 10 mixings were sufficient to produce homogeneous LNPs with high ASO loading, but further increases in mixing rate or count did not affect particle size and %EE (Figures 1D-1F). Therefore, for the following studies, the conditions of ethanol-buffer injection followed by 10 mixings at 0.5 ml / s were selected.
[0178] Example 2 HTS of ASO-loaded LNP preparations To investigate the influence of formulation parameters on key quality attributes of LNPs, we designed an HTS workflow that enables streamlined preparation and characterization of these formulations (Figure 2). ASOs were first dissolved in citrate buffer at pH 4.0, lower than the pKa (6.4) of MC3, to allow the lipids to become positively charged and promote charge-mediated complexing. The solution was then neutralized with phosphate buffer before analysis.
[0179] For typical screening, 32 different samples (three replicates each) varying in two levels of total lipid concentration, four levels of ASO loading adjusted by the N / P ratio, and four levels of PEGylated lipid content were screened in parallel in a 96-well plate (Figure 3A). Among the three formulation parameters investigated, PEGylated lipid was essential for LNP formation because large multi-modal aggregates were generated when PEG was not incorporated into the lipid composition (Figures 3C - 3D, Figure 4). Significantly increasing the PEGylated lipid content (P < 0.0001) decreased the average particle size, i.e., lipids containing 1.5, 3, and 5 mol% DSPE-PEG 2000 resulted in LNP diameters of approximately 120, approximately 80, and approximately 60 nm, respectively (Figures 3C - 3D). However, the polydispersity also increased, and 5 mol% DSPE-PEG 2000 even generated subpopulations, probably due to the formation of small DSPE-PEG 2000 micelles (Figure 3C). See, e.g., Johnsson et al., 2003, Biophys J 85(6):3839 - 47; Gill et al., 2015, J Drug Target 23(3):222 - 31.
[0180] On the other hand, the %EE of ASO was mainly determined by the N / P ratio. An N / P ratio higher than 1 with excess complexing sites in MC3 resulted in a %EE of over 80%. On the other hand, a two-fold excess of ASO-1 beyond the charge balance point significantly decreased the %EE to approximately 50% (Figure 3E). Similar results were observed when MC3 was replaced with another cationic lipid, DOTAP (Figures 5A - 5C), or when ASO-1 was replaced with ASO-2 (Figures 6A - 6C), demonstrating the robustness of the HTS results.
[0181] Example 3 Verification of HTS Results by Scale-up LNP Preparation Next, the effect of the screened formulation parameters on LNP quality attributes was examined by comparing the results from the HTS approach with those from the microfluidic formulation apparatus. The two methods showed similar results: (1) LNP size decreased but polydispersity increased as PEG content increased (Figure 7A); (2) LNP size remained stable with increasing total lipid concentration up to 2 mM (Figure 7B); (3) LNP size remained stable when the N / P ratio < 2 (Figure 7C); (4) excessive ASO loading (N / P ratio < 1) resulted in a significant decrease in %EE (Figure 7D); and (5) LNPs showed similar structures when prepared with the same N / P ratio and PEGylated lipid content (Figure 7E). Furthermore, the HTS approach showed linear regression R 2 The strong correlation with >0.9 (Figure 7A) successfully predicted the dependence of particle size and polydispersity on PEGylated lipid content.
[0182] Example 4 Stability screening of ASO-loaded LNPs To further investigate the effect of different particle sizes on formulation stability, ASO-1 loaded LNPs prepared with various PEG contents were diluted 10-fold in PBS, incubated at 4°C or 40°C, and the particle size distribution was monitored over two weeks. Since the N / P ratio remained above 1 and the %EE of ASO was approximately 90%, ASO leakage from the LNPs during stability testing could be quantified. As shown in Figures 8A-8B, 1.5 or 3 mol% DSPE-PEG 2000 Similarly, LNPs prepared by high-throughput solvent injection or NanoAssemblr®, including DSPE-PEG, retained their initial average particle size (Figure 8A) and polydispersity (Figure 8B) during incubation at 4°C. 2000 LNPs containing 1.5 mol% DSPE-PEG showed an increase in particle size after one week, but maintained a constant polydispersity (Figure 9). 2000 LNPs containing the same substance also showed minimal ASO leakage within the first three days, but 3 and 5 mol% DSPE-PEG after two weeks. 2000It showed similar levels of ASO leakage as LNPs containing (Figure 10). No ASO leakage was detected at 4°C for one month.
[0183] The solvent injection method was selected for high-throughput preparation of LNP formulations because the phase mixing process could be performed by a robotic liquid handler. Compared to manual pipetting, the multi-channel liquid handler enabled high-throughput parallel processing of 96 samples, achieving uniform liquid dispensing and mixing across the wells. A key process involved rapid and thorough mixing of the intermiscibility phase, e.g., ethanol dissolving the lipids and aqueous buffer dissolving the nucleic acids, to promote the self-assembly of lipids into a spherical lipid layer and nanoparticle structure. This method is widely used for liposome preparation, and adjusting the ethanol phase to less than 50% by volume produced uniform nanoparticles. Increasing the ethanol phase ratio and / or lipid concentration resulted in the generation of larger particles or aggregates, possibly due to inefficient phase mixing, as also shown by the results of slow buffer-ethanol injection (Figures 1A-1B). Insights from the automated mixing process using the liquid handler correlated highly with the results of LNPs prepared by the microfluidic method. The flow rate ratio (FRR, aqueous vs. organic flow rate) is one of the key formulation parameters during microfluidic preparation, with lower FRRs producing larger particles. Slow-rate buffer-ethanol injection resulted in a low FRR (Fluid-Rate Reaction). Therefore, the automated mixing conditions were optimized, and ethanol-buffer injection was set to 0.5 ml / s under a 1 / 3 ethanol / aqueous volume ratio (25 vol% ethanol), followed by 10 pipettings to achieve efficient phase mixing and produce homogeneous particles with high encapsulation efficiency.
[0184] Next, a streamlined workflow was developed to screen formulation variables, including total lipid concentration, lipid composition, and ASO loading, for optimal quality attributes of ASO-loaded LNPs. For this purpose, the particle size distribution and %EE of ASO were analyzed using high-throughput DLS and OD, respectively. 260The conditions for generating uniform nanoparticles with a high ASO load were determined by measurement. Screening results showed that the PEGylated lipid content significantly affected the particle size distribution (Figures 3B-3D, 5A-5B, 6A-6B). DSPE-PEG was incorporated at 1.5 mol% of the total lipids. 2000 The PEG produced unimodal nanoparticles with an average diameter of approximately 120 nm, but more PEG increased polydispersity. Ionizable lipids consisting of tertiary amine structures are increasingly being used in lipid-based delivery systems for nucleotides, exhibiting better intracellular delivery efficiency and lower cytotoxicity than persistently charged cationic lipids. See, for example, Cullis & Hope, 2017, Mol. Ther. 25(7):1467-1475; Sabnis et al. 2018, Mol Ther. 26(6):1509-1519; Semple et al., 2010, Nature Biotechnology, 28(2):172-176. Consistent with the charge-mediated complexing loading mechanism, the screening results showed ASO encapsulation determined by the N / P ratio, with an N / P ratio of 1 indicating approximately 90% %EE (Figure 3E, 5C, 6C), corresponding to the loading capacity of 0.29 mg of RTR3833 / mg lipid (1.5 mol% DSPE-PEG). 2000 (Contains 2 mM total lipids).
[0185] Importantly, the results from the HTS approach successfully predicted the results from microfluidic formulation systems, which are increasingly being used to prepare nanoparticle formulations with scalable production. See, for example, Belliveau et al., 2012, Mol. Ther. Nucleic Acids, 1, e37; van Swaay & de Mellow, 2013, Lab Chip 13(5):752-67. Both methods showed a similar dependence of LNP size on PEGylated lipid content (Figure 7A), total lipid concentration (Figure 7B), and N / P ratio (Figure 7C), and the %EE of ASO was similarly adjusted by the N / P ratio (Figure 7D). The two methods also produced LNPs with similar structures under the same formulation parameters (Figure 7E). Furthermore, these ASO-loaded LNPs showed a stable particle size distribution (Figures 8A-8B) and leakage of approximately 20% of the encapsulated ASO over two weeks of storage at 40°C (Figure 10). However, compared to microfluidic preparation, the HTS approach demonstrated significant advantages in saving approximately 10 times the raw materials while increasing preparation and analytical output by approximately 100 times (parallel processing of 96 samples in a microplate compared to a single microfluidic run), indicating great potential for early-stage formulation screening (Figure 11). Based on the screening results, it was determined that 1.5 mol% DSPE-PEG2000 and an N / P ratio ≥ 1 produced the optimal LNP formulation with uniform and stable particle size and high ASO loading. The same opinion remained valid even after introducing different lipids and other ASOs into the HTS system, suggesting that this screening platform can be expanded to include various types of carriers and cargoes such as siRNA and single guide RNA.
[0186] The HTS screening approach demonstrated a reproducible formulation platform for preparing LNPs. The convertible results from the automated injection platform to microfluidic preparations created a seamless workflow to support screening and scale-up formulations, avoiding bridge studies resulting from formulation mismatches. The next step is to integrate the current workflow with downstream in vitro screening to correlate the physicochemical attributes of ASO-loaded LNPs with therapeutic efficacy. Furthermore, the workflow can be further improved to address more formulation attributes, such as simultaneous quantification of both APIs and excipients by zeta potential and liquid chromatography strategies. (Yamamoto et al., 2011 J Chromatogr B Analyt Technol Biomed Life Sci 879(20), 3620-5, Li et al., 2019, J Chromator A 1601:145-154.)
[0187] In this embodiment, a high-throughput approach was developed to screen formulation parameters and address quality attributes of ASO-loaded LNPs. A streamlined workflow, beginning with automated liquid dispensing and mixing, followed by high-throughput particle size and ASO encapsulation analysis, identified PEGylated lipid content and N / P ratio as key determinants of particle size distribution and encapsulation efficiency, respectively. Furthermore, the HTS results successfully predicted outcomes from scale-up preparations using microfluidics. Robust screening results, along with significant material savings and improved analytical output, suggest great potential for advancing the development of lipid-based nanoparticle formulations with this approach.
[0188] Example 5 Alternative methods for quantifying ASO encapsulation The quantification of ASO encapsulation was determined using a fluorescence plate reader. In short, ASO-loaded LNPs were prepared by high-throughput solvent injection, then diluted 50-fold with TE buffer and mixed with an equal volume of 5000-fold diluted Sybr-gold fluorescence probe. Unencapsulated ASO was quantified using a fluorescence plate reader (Ex / Em = 495 / 550 nm). The LNPs were then destroyed by direct addition of an equal volume of 10000-fold diluted Sybr-gold in 1 vol.% Triton TE (i.e., maintaining a final probe dilution of 10000-fold and a Triton concentration of 0.5 vol.%) (Figure 12A). Fluorescence measurements were then performed to quantify the total ASO. The encapsulation efficiency (%EE) was calculated as follows: TIFF2023552815000002.tif15170
[0189] The calculations showed comparable %EE results for two different LNP formulations prepared with different N / P ratios using fluorescence and UV-Vis methods (Figure 12B). Results are expressed as mean ± SD, n=2;ns, not significant (analyzed by two-way ANOVA followed by Sidak's multiple comparison).
[0190] Example 6 HiBiT peptide loading LNP preparation HTS To investigate the influence of formulation parameters on key quality attributes of liposomes, we designed an HTS workflow that would enable the streamlined preparation and characterization of these formulations. HiBiT was first dissolved in 20 mM histidine-acetate buffer supplemented with 150 mM NaCl (pH 5.5) and dispensed into microwell plates using a robotic liquid handler. Lipid mixtures were prepared as in Example 2 (Figure 13A).
[0191] For typical screening, 32 different samples (three replicates each) varying with eight combinations of four LNP formulations and PEGylated lipids, shielded PEGylated lipids, and PEGylated lipids conjugated with azides were screened in parallel in 96-well plates (Figure 13B). Of the eight formulation parameters investigated, PEGylated lipids were necessary for LNP formation because large, multimodal aggregates were formed when PEG was not incorporated into the lipid composition (Figure 13C). Quantification of free peptide concentrations before and after purification yielded average purification efficiencies of approximately 98% and 61% for gel filtration and dialysis, respectively (Figures 13D-13F). Particle recovery rates were generally between 80-120%, except for low values for aggregated samples prepared without PEGylated lipids (Figure 13G). Furthermore, the particle size distribution remained constant even after purification by gel filtration (Figure 13H). References K. Sridharan, NJ Gogtay, Therapeutic nucleic acids: current clinical status, Br J Clin Pharmacol 82(3)(2016)659-72. A. Goyon, P. Yehl, K. Zhang, Characterization of therapeutic oligonucleotides by liquid chromatography, J Pharm Biomed Anal 182(2020)113105. C. Chakraborty, ARSharma, G. Sharma, CGPDoss, SSLee, Therapeutic miRNA and siRNA: Moving from Bench to Clinic as Next Generation Medicine, Mol Ther Nucleic Acids 8(2017)132-143. CIESmith, R. Zain, Therapeutic Oligonucleotides: State of the Art, Annu Rev Pharmacol Toxicol 59(2019)605-630. D.Adams,A.Gonzalez-Duarte,WDO'Riordan,CCYoung,M.Ueda,AVKristen,I.Tournev,HHSchmidt,T.Coelho,JLBerk,KPLin,G.Vita,S.Attarian,V.Plante-Bordeneuve,MMezei,JJBuranstodes,THMJB. agan,3rd,BJKim,J.Oh,Y.Parman,Y.Sekijima,PNHawkins,SDSolomon,M.Polydefkis,PJDyck,PJGandhi,S.Goyal,J.Chen,ALStrahs,SVNochur,MTSweetser,PPGarg,AKVaishnaw,JAGollob,Patiran,OBSRAN RNAi Therapeutic,for Hereditary Transthyretin Amyloidosis,N Engl J Med 379(1)(2018)11-21. U.Sahin,K.Kariko,O.Tureci,mRNA-based therapeutics--developing a new class of drugs,Nat Rev Drug Discov 13(10)(2014)759-80. U.Sahin,E.Derhovanessian,M.Miller,BPKloke,P.Simon,M.Lower,V.Bukur,ADTadmor,U.Luxemburger,B.Schrors,T.Omokoko,M.Vormehr,J.Al brecht,A.Paruzynski,ANKuhn,J.Buck,S.Heesch,KHSchreeb,F.Muller,I.Ortseifer,I.Vogler,E.Godehardt,S.Attig,R.Rae,A.Breitkreuz,J .Tolliver,M.Suchan,G.Martic,A.Hohberger,P.Sorn,J.Diekmann,J.Ciesla,O.Waksmann,AKBruck,M.Witt,M.Zillgen,A.Rothermel,B.Kasema nn,D.Langer,S.Bolte,M.Dicken,S.Kreiter,R.Nemecek,J.Gebhardt,S.Grabbe,J.Holler,J.Utical,J.Huber,J.Loquai,O.Tureci,Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer,Nature 547(7662)(2017)222-226. N.Pardi,MJHogan,FWPorter,D.Weissman,mRNA vaccines-a new era in vaccinology,Nat Rev Drug Discov 17(4)(2018)261-279. KADowd,SYKo,KMMorabito,ESYang,RSPelc,CRDeMaso,LRCastilho,P.Abbink,M.Boyd,RNityanandam,DNGordon,JRG authors,X.Chen,JPTodd,Y.Tsybovsky,A.Harris,YSHuang,S.Higgs,DLVanlandingham,H.Andersen,MGLewis,R.De La Barrera,KHEckels,RGJarman,MCNason,DHBarouch,M.Roederer,WPKong,JRMascola,TCPierson,BSGraham,Rapid development of a DNA vaccine for Zika virus,Science 354(6309)(2016)237-240. JMRichner,S.Himansu,KADowd,SLButler,V.Salazar,JMFox,JGJulander,WWTang,S.Shresta,TCPierson,GCiaramella,MSDiamond,Modified mRNA Vaccines Protect against Zika Virus Infection,Cell 168(6)(2017)1114-1125 e10. A.Patel,E.L.Reuschel,K.A.Kraynyak,T.Racine,D.H.Park,V.L.Scott,J.Audet,D.Amante,M.C.Wise,A.A.Keaton,G.Wong,D.O.Villarreal,J.Walters,K.Muthumani,D.J.Shedlock,M.A.de La Vega,R.Plyler,J.Boyer,K.E.Broderick,J.Yan,A.S.Khan,S.Jones,A.Bello,G.Soule,K.N.Tran,S.He,K.Tierney,X.Qiu,G.P.Kobinger,N.Y.Sardesai,D.B.Weiner,Protective Efficacy and Long-Term Immunogenicity in Cynomolgus Macaques by Ebola Virus Glycoprotein Synthetic DNA Vaccines,J Infect Dis 219(4)(2019)544-555. M.D.Shin,S.Shukla,Y.H.Chung,V.Beiss,S.K.Chan,O.A.Ortega-Rivera,D.M.Wirth,A.Chen,M.Sack,J.K.Pokorski,N.F.Steinmetz,COVID-19 vaccine development and a potential nanomaterial path forward,Nat Nanotechnol(2020). J.Wang,Z.Lu,M.G.Wientjes,J.L.Au,Delivery of siRNA therapeutics:barriers and carriers,The AAPS journal 12(4)(2010)492-503. M.Durymanov,J.Reineke,Non-viral Delivery of Nucleic Acids:Insight Into Mechanisms of Overcoming Intracellular Barriers,Front Pharmacol 9(2018)971. A.Akinc,M.A.Maier,M.Manoharan,K.Fitzgerald,M.Jayaraman,S.Barros,S.Ansell,X.Du,M.J.Hope,T.D.Madden,B.L.Mui,S.C.Semple,Y.K.Tam,M.Ciufolini,D.Witzigmann,J.A.Kulkarni,R.van der Meel,P.R.Cullis,The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs,Nat Nanotechnol 14(12)(2019)1084-1087. A.C.Anselmo,S.Mitragotri,Nanoparticles in the clinic:An update,Bioeng Transl Med 4(3)(2019)e10143. Liposome drug products:chemistry,manufacturing,and controls;human pharmacokinetics and bioavailability;and labeling documentation,U.S.Food and Drug Administration,2018. T.M.Allen,C.Hansen,F.Martin,C.Redemann,A.Yau-Young,Liposomes containing synthetic lipid derivatives of poly(ethylene glycol)show prolonged circulation half-lives in vivo,Biochim Biophys Acta 1066(1)(1991)29-36. O.Garbuzenko,Y.Barenholz,A.Priev,Effect of grafted PEG on liposome size and on compressibility and packing of lipid bilayer,Chem Phys Lipids 135(2)(2005)117-29. M.L.Immordino,F.Dosio,L.Cattel,Stealth liposomes:review of the basic science,rationale,and clinical applications,existing and potential,Int J Nanomedicine 1(3)(2006)297-315. A.Schroeder,C.G.Levins,C.Cortez,R.Langer,D.G.Anderson,Lipid-based nanotherapeutics for siRNA delivery,J Intern Med 267(1)(2010)9-21. P.R.Cullis,M.J.Hope,Lipid Nanoparticle Systems for Enabling Gene Therapies,Mol Ther 25(7)(2017)1467-1475. M.Johnsson,K.Edwards,Liposomes,disks,and spherical micelles:aggregate structure in mixtures of gel phase phosphatidylcholines and poly(ethylene glycol)-phospholipids,Biophys J 85(6)(2003)3839-47. K.K.Gill,A.Kaddoumi,S.Nazzal,PEG-lipid micelles as drug carriers:physiochemical attributes,formulation principles and biological implication,J Drug Target 23(3)(2015)222-31. K.Yang,J.T.Delaney,U.S.Schubert,A.Fahr,Fast high-throughput screening of temoporfin-loaded liposomal formulations prepared by ethanol injection method,J Liposome Res 22(1)(2012)31-41. M.A.Schubert,C.C.Muller-Goymann,Solvent injection as a new approach for manufacturing lipid nanoparticles--evaluation of the method and process parameters,Eur J Pharm Biopharm 55(1)(2003)125-31. A.A.Mokhtarieh,J.Lee,S.Kim,M.K.Lee,Preparation of siRNA encapsulated nanoliposomes suitable for siRNA delivery by simply discontinuous mixing,Biochim Biophys Acta Biomembr 1860(6)(2018)1318-1325. C.Jaafar-Maalej,R.Diab,V.Andrieu,A.Elaissari,H.Fessi,Ethanol injection method for hydrophilic and lipophilic drug-loaded liposome preparation,J Liposome Res 20(3)(2010)228-43. I.V.Zhigaltsev,N.Belliveau,I.Hafez,A.K.Leung,J.Huft,C.Hansen,P.R.Cullis,Bottom-up design and synthesis of limit size lipid nanoparticle systems with aqueous and triglyceride cores using millisecond microfluidic mixing,Langmuir 28(7)(2012)3633-40. S.Sabnis,E.S.Kumarasinghe,T.Salerno,C.Mihai,T.Ketova,J.J.Senn,A.Lynn,A.Bulychev,I.McFadyen,J.Chan,O.Almarsson,M.G.Stanton,K.E.Benenato,A Novel Amino Lipid Series for mRNA Delivery:Improved Endosomal Escape and Sustained Pharmacology and Safety in Non-human Primates,Mol Ther 26(6)(2018)1509-1519. S.C.Semple,A.Akinc,J.Chen,A.P.Sandhu,B.L.Mui,C.K.Cho,D.W.Sah,D.Stebbing,E.J.Crosley,E.Yaworski,I.M.Hafez,J.R.Dorkin,J.Qin,K.Lam,K.G.Rajeev,K.F.Wong,L.B.Jeffs,L.Nechev,M.L.Eisenhardt,M.Jayaraman,M.Kazem,M.A.Maier,M.Srinivasulu,M.J.Weinstein,Q.Chen,R.Alvarez,S.A.Barros,S.De,S.K.Klimuk,T.Borland,V.Kosovrasti,W.L.Cantley,Y.K.Tam,M.Manoharan,M.A.Ciufolini,M.A.Tracy,A.de Fougerolles,I.MacLachlan,P.R.Cullis,T.D.Madden,M.J.Hope,Rational design of cationic lipids for siRNA delivery,Nature biotechnology 28(2)(2010)172-6. N.M.Belliveau,J.Huft,P.J.Lin,S.Chen,A.K.Leung,T.J.Leaver,A.W.Wild,J.B.Lee,R.J.Taylor,Y.K.Tam,C.L.Hansen,P.R.Cullis,Microfluidic Synthesis of Highly Potent Limit-size Lipid Nanoparticles for In Vivo Delivery of siRNA,Mol Ther Nucleic Acids 1(2012)e37. D.van Swaay,A.deMello,Microfluidic methods for forming liposomes,Lab Chip 13(5)(2013)752-67. E.Yamamoto,K.Hyodo,N.Ohnishi,T.Suzuki,H.Ishihara,H.Kikuchi,N.Asakawa,Direct,simultaneous measurement of liposome-encapsulated and released drugs in plasma by on-line SPE-SPE-HPLC,J Chromatogr B Analyt Technol Biomed Life Sci 879(30)(2011)3620-5. L.Li,J.P.Foley,R.Helmy,Simultaneous separation of small interfering RNA and lipids using ion-pair reversed-phase liquid chromatography,J Chromatogr A 1601(2019)145-154.
Claims
1. 1. An optimized high throughput screening method for producing lipid nanoparticle (LNP) preparations or for encapsulating a payload into an LNP preparation, comprising: a. obtaining a first solution comprising an aqueous phase; b. obtaining a second solution comprising an organic phase and a plurality of molecules capable of self-assembling, the self-assembling molecules comprising at least one lipid component, the first solution and the second solution being miscible; c. dissolving at least one payload molecule in either the first solution or the second solution, wherein the payload is a nucleic acid; d. Using a robotic liquid handler to prepare and dispense said phases having different compositions into multiple wells; e. mixing the first solution and the second solution to obtain lipid nanoparticles encapsulating the payload using the robotic liquid handler under conditions suitable for LNP formation, where at least one of the following conditions: type of self-assembling molecules, composition ratio of the self-assembling molecules, ratio and / or concentration of the self-assembling molecules to the payload, phase, buffer type and pH selection, injection order, injection rate, mixing rate, volume, phase ratio, injection duration, and mixing duration are varied between different wells; f. Measuring at least one of the entrapment efficiency, particle size distribution, purification and particle recovery, and formulation stability of said LNPs; g. determining optimal parameters for producing said LNP preparation; and h. Producing the LNP preparation based on the optimal parameters. An optimized high throughput screening method comprising:
2. 1. A method for producing a lipid nanoparticle (LNP) preparation, comprising: a. obtaining a first solution comprising an aqueous phase; b. obtaining a second solution comprising an organic phase and a plurality of molecules capable of self-assembly, the plurality of molecules capable of self-assembly comprising at least one lipid component, and the first solution and the second solution being miscible; c. dissolving at least one payload molecule in either the first solution or the second solution, wherein the payload is a nucleic acid; d. Using a robotic liquid handler to prepare and dispense said phases having different compositions into multiple wells; e. mixing the first solution and the second solution to obtain lipid nanoparticles encapsulating the payload using the robotic liquid handler under conditions suitable for LNP formation, where at least one of the following conditions: type of self-assembling molecules, composition ratio of the self-assembling molecules, ratio and / or concentration of the self-assembling molecules to the payload, phase, buffer type and pH selection, injection order, injection rate, mixing rate, volume, phase ratio, injection duration, and mixing duration are varied between different wells; f. Measuring at least one of the entrapment efficiency, particle size distribution, purification and particle recovery, and formulation stability of said LNPs; g. determining optimal parameters for producing said LNP preparation; and h. Producing the LNP preparation based on the optimal parameters. A manufacturing method comprising:
3. The payload: a. an oligonucleotide, optionally wherein said oligonucleotide is an antisense molecule, and further optionally wherein said oligonucleotide is an shRNA; or said oligonucleotide is an siRNA; and / or said oligonucleotide is about 10 to about 30 nucleotides in length; and / or b. mRNA, optionally the size of the mRNA is about 500-3000 nucleotides in length or about 1 kb to about 2 kb; The method according to claim 1 or 2.
4. The payload is: a. the first solution, optionally wherein the first solution is an aqueous buffer and / or the first solution comprises a pH-adjusted buffer and an osmolality-adjusted buffer; and / or b. the second solution, optionally wherein the organic phase of the second solution comprises methanol and / or ethanol; The method according to any one of claims 1 to 3, wherein the hydroxyl group is dissolved in water.
5. 5. The method of claim 1, wherein the lipid component is composed of at least one lipid molecule, optionally wherein the at least one lipid molecule is selected from cationic lipid species, ionizable lipid species, non-cationic lipid species, phospholipid species, and non-phospholipid species; and / or the second solution comprises two or more types of lipids.
6. 6. The method of any one of claims 1 to 5, wherein the total lipid concentration is varied, optionally the total lipid concentration is varied between about 0.4 and about 4 mM.
7. 7. The method of any one of claims 1 to 6, wherein the percentage of lipid that is PEGylated is varied, optionally the percentage of lipid that is PEGylated varies between about 0.5% and about 5% of the total lipid composition.
8. 8. The method of any one of claims 1 to 7, wherein the N:P ratio of the payload is varied, optionally the N:P ratio varies between about 0.5 and about 5.
9. The LNPs are a. polymeric lipid nanoparticles; b. Liposomes; or c. A lipoprotein nanoparticle; The method according to any one of claims 1 to 8.
10. The method according to any one of claims 1 to 9, wherein the first solution is injected into the second solution and / or the second solution is injected into the first solution.
11. The optimal parameters are: a. a parameter that results in an encapsulation efficiency of the payload of greater than 80%; or b. parameters that result in LNPs with a mean diameter of 80-200 nm, with a monomodal size distribution and a polydispersity of less than about 30%; The method according to any one of claims 1 to 10.
12. The method of any one of claims 1 to 11, wherein the LNPs maintain similar size distribution and payload loading for at least one month under storage in solution at 4°C.
13. A medicine for treating a patient, comprising an LNP preparation produced by a method according to any one of claims 2 to 12.
14. A workflow for multi-parameter HTS screening for LNP formation, comprising: (i) Robotic liquid handlers; (ii) at least one instrument capable of measuring the desired LNP characteristic; and (iii) at least one microplate comprising a plurality of microwells; the robotic liquid handler is capable of injecting a plurality of solutions into each of the microwells; The parameter is systematically varied between microwells; and The desired LNP properties can be measured for each microwell; and the LNP comprises a nucleic acid payload; and The plurality of parameters are selected from the total lipid content, the type of self-assembling molecule, where the self-assembling molecule comprises at least one lipid component; the composition ratio of the self-assembling molecule; and / or the ratio and / or concentration of the self-assembling molecule to the payload; the choice of phase, buffer type and pH, injection sequence, volume and speed, and mixing duration. Workflow.
15. The workflow of claim 14 , wherein the desired LNP properties are selected from the group consisting of average particle size, particle size distribution, encapsulation efficiency, and particle stability.
16. 16. The workflow of claim 14 or 15, wherein the instrument is capable of either Dynamic Light Scattering (DLS), Ultraviolet-Visible (UV-Vis) spectroscopy or Fluorescence spectroscopy.
